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Resumo 
 
 
O desenvolvimento de genéricos reveste-se de grande 
complexidade pela demanda de qualidade associada a qualquer 
produto farmacêutico acrescida da complexa interpretação de 
situação jurídica (patentes), da seleção de um vasto número de 
moléculas e tecnologias que trarão um claro custo-benefício e dos 
exigentes prazos para as colocar em mercados, muitas vezes com 
diferentes requisitos regulatórios. 
Esta tese irá providenciar uma visão geral sobre um método 
standard numa indústria de desenvolvimento farmacêutico. O 
presente trabalho tem como objetivo descrever os pontos gerais 
de um desenvolvimento galénico, seguido por exemplos práticos, 
de forma a avaliar um projeto desde o seu estado conceptual até 
à fase de ensaio clínico. 
De forma a dar uma visão clara de desenvolvimento galénico 
numa instalação de estado da arte, este trabalho irá abordar 
processos usados na análise da viabilidade de projetos, 
formulação, processos de fabrico e submissão de dossiers de 
produtos investigacionais. 
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Abstract 
 
 
The development of generics is a very complex area due to the 
demand for quality associated to any pharmaceutical product 
added to the complex interpretation of legal situation (patents), the 
selection of a large number of molecules and technologies that will 
bring a clear cost-benefit and the demanding deadlines for placing 
them in markets, often with different regulatory requirements. 
This thesis will provide a general view of a standardized method 
used in a pharmaceutical development company. The present 
work intends to describe the general points of the galenical 
development followed by practical examples of this process, 
evaluating the project from its initial conceptual phase until clinical 
trial. 
In order to portrait a clear picture of the galenical development on 
a state of the art facility, the work will access current processes 
used for project viability analysis, formulation, manufacturing 
processes and IMPD submission 
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1.!Introduction 
In order to accomplish my curricular plan for Master degree at University of Aveiro’s Training 
Program in Pharmaceutical Medicine, my work focus on the development of a Project on 
Pharmaceutical development. More precisely about galenical development, area in which I 
presently work in Bluepharma.  
This thesis will provide a general view of a standardized methods used in a pharmaceutical 
development company. This work intends to describe the general points of the galenical 
development followed by practical examples of this process, evaluating the project from its 
initial conceptual phase until clinical trial. The data of practical examples were obtained from 
pharmaceutical development reports, wherefore the confidentiality of the name of drug 
product or the drug substance were respected.  
In order to portrait a clear picture of the galenical development on a state of the art facility, 
the work will access current processes used for project viability analysis, formulation, 
manufacturing processes and IMPD submission. 
The data compiled during the elaboration of this thesis will allow Bluepharma to have a clear 
picture of the current pharmaceutical development. By accessing the existing strengths and 
weaknesses will yield a possible optimisation of the pharmaceutical development process. 
 
1.1! Objectives 
This thesis aims at describe the process of developing a project since it emerges as an idea 
until it is undergoes to clinical trial. Therefore, the issues covered by this thesis enclose the 
projects viability, a project management approach of the initial idea where it is decided if 
the project continues or not; a galenical development stage, where is briefly described the 
main critical points of formulation development; a scale-up and GMP production, where the 
collaborative work between galenical development and production have a crucial role in the 
success of the production of validation batches and finally a importance of the data 
generated by development department in the creation of the Investigational Medicinal 
Product Dossiers.  
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1.2! Project Structure 
This report is divided in five sections. The Introduction, will briefly describe the objectives 
with the elaboration of this project work, as do the current state-of–the-art of formulation 
development and a short description of the host company. Project viability is described in 
section two, having as sub-topics the definition of markets, definition of timelines and 
milestones and economical viability of the project.  Section three have a summarized 
approach to galenical development with themes as characterization of drug product (Active 
Substance and Excipients), manufacturing process, formulation development and 
optimization of galenical development processes. In section four, the elaboration of IMPDs 
is addressed as the documentation needed for the shipping of the investigational products. 
The accomplishment of the proposed objectives is discussed in final notes, on section five, 
the last section.  
 
1.3! Pharmaceutical Development 
The goal of pharmaceutical development activities is to design a quality product and its 
manufacturing process to consistently deliver the intended performance and meet the 
needs of patients, healthcare professionals, regulatory authorities and internal customers’ 
requirements. (ICH Q9, 2008) 
The information and knowledge gained from pharmaceutical development studies and 
manufacturing experience provide scientific understanding to support the establishment of 
the design space (multidimensional combination and interaction of input variables (e.g., 
material attributes) and process parameters that have been demonstrated to provide 
assurance of quality), specifications, and manufacturing controls.  
Information from pharmaceutical development studies can be a basis for quality risk 
management. It is important to recognize that quality cannot be tested into products; i.e., 
quality should be built in by design. Changes in formulation and manufacturing processes 
during development and lifecycle management should be looked upon as opportunities to 
gain additional knowledge and further support establishment of the design space. Similarly, 
inclusion of relevant knowledge gained from experiments giving unexpected results can 
also be useful. Design space is proposed by the applicant and is subject to regulatory 
assessment and approval. Working within the design space is not considered as a change. 
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Movement out of the design space is considered to be a change and would normally initiate 
a regulatory post approval change process.  
The Pharmaceutical Development should describe the knowledge that establishes that the 
type of dosage form selected and the formulation proposed are suitable for the intended 
use.  
At a minimum, those aspects of drug substances, excipients, container closure systems, 
and manufacturing processes that are critical to product quality should be determined and 
control strategies justified. Critical formulation attributes and process parameters are 
generally identified through an assessment of the extent to which their variation can have 
impact on the quality of the drug product.  
In addition, the applicant can choose to conduct pharmaceutical development studies that 
can lead to an enhanced knowledge of product performance over a wider range of material 
attributes, processing options and process parameters. Inclusion of this additional 
information provides an opportunity to demonstrate a higher degree of understanding of 
material attributes, manufacturing processes and their controls. This scientific 
understanding facilitates establishment of an expanded design space. In these situations, 
opportunities exist to develop more flexible regulatory approaches, for example, to facilitate:  
!! risk-based regulatory decisions (reviews and inspections);  
!! manufacturing process improvements, within the approved design space described 
in the dossier, without further regulatory review;  
!! reduction of post-approval submissions; real-time quality control, leading to a 
reduction of end-product release testing. To realise this flexibility, the applicant 
should demonstrate an enhanced knowledge of product performance over a range 
of material attributes, manufacturing process options and process parameters. (ICH 
Q8(R2), August 2009) 
In Pharmaceutical Development, the product should be designed to meet patients’ needs 
and the intended product performance. Strategies for product development vary from 
company to company and from product to product. The approach to, and extent of, 
development can also vary and should be outlined in the submission. An applicant might 
choose either an empirical approach or a more systematic approach to product 
development, or a combination of both. A more systematic approach to development (also 
defined as quality by design) can include, for example, incorporation of prior knowledge, 
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results of studies using design of experiments, use of quality risk management, and use of 
knowledge management throughout the lifecycle of the product. Such a systematic 
approach can enhance achieving the desired quality of the product and help the regulators 
to better understand a company’s strategy. Product and process understanding can be 
updated with the knowledge gained over the product lifecycle.  
A greater understanding of the product and its manufacturing process can create a basis 
for more flexible regulatory approaches. The degree of regulatory flexibility is predicated on 
the level of relevant scientific knowledge provided in the registration application. It is the 
knowledge gained and submitted to the authorities, and not the volume of data collected, 
that forms the basis for science- and risk-based submissions and regulatory evaluations. 
Nevertheless, appropriate data demonstrating that this knowledge is based on sound 
scientific principles should be presented with each application.  
Pharmaceutical development should include, at a minimum, the following elements:  
!! Defining the quality target product profile (QTPP) as it relates to quality, safety and 
efficacy, considering e.g., the route of administration, dosage form, bioavailability, 
strength, and stability;  
!! Identifying potential critical quality attributes (CQAs) of the drug product, so that 
those product characteristics having an impact on product quality can be studied 
and controlled;  
!! Determining the critical quality attributes of the drug substance, excipients etc., and 
selecting the type and amount of excipients to deliver drug product of the desired 
quality;  
!! Selecting an appropriate manufacturing process;  
!! Defining a control strategy. (ICH Q8(R2), August 2009) 
 
Development is divided into chemical and pharmaceutical development. The former covers 
the development of the active pharmaceutical ingredient (API). This is the ingredient which 
is responsible for a drug’s therapeutic effect. Pharmaceutical development, on the other 
hand, deals with the development of the final drug product. Its administration form, e.g. a 
pill, a spray, or a liquid for injection, and dosage are essential for the therapeutic effect to 
unfold. (Ziegler, 2014) 
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The Pharmaceutical Development includes two major areas: the galenical development and 
the analytical development. The focus of this project is the galenical development approach 
with practical examples of one development done for a generic product in Bluepharma.  
  
 
6 
1.4! Host Company – Bluepharma 
Bluepharma is a Portuguese capital pharmaceutical company, based in Coimbra. 
Bluepharma initiated its activity in February 2001, when a group of professionals, connected 
with the pharmaceutical industry, bought a state-of-the-art industrial unit from the German 
giant, Bayer. 
Bluepharma concentrates its efforts on the manufacturing, development and marketing of 
pharmaceutical drugs. With over 30 years of experience in producing pharmaceutical 
products, they guarantee standards of the highest quality, based on the know-how of our 
technical staff, and vision and dynamism of our management team. 
Bluepharma's activities are carried out in 3 distinct areas: 
!! Producing pharmaceutical drugs for Bluepharma and other companies; 
!! Research, development and registration of pharmaceutical drugs; 
!! Marketing of generic pharmaceuticals. 
Bluepharma is committed to systematically ensuring the quality of manufactured and 
distributed medicinal products; to respecting the environment as well as safeguarding the 
working conditions of its employees. This is achieved through the implementation of a 
Quality, Environment, Health and Safety System, supported by ISO Norms 9001, ISO 
14001 and OHSAS 18001, by the Good Manufacturing Practices and by other applicable 
legislation. 
Their mission is to market pharmaceutical products of the highest quality at competitive 
prices, contributing for the rationalization of expenses in the health sector and 
simultaneously to the improvement of the life quality of populations. (Bluepharma Site)  
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2.!Project Viability 
At Bluepharma, before a project of development starts, a multidisciplinary group is formed 
to discuss the viability of the project (Evaluation Meetings). The team include one member 
of each department: galenical development, analytical development, business 
development, quality management, project management, production (manufacturing and 
packaging), regulatory affairs and production management. Each one expresses their 
technical opinion about the viability and feasibility of the project. The conclusions of that 
meetings are thereafter communicated to top management which decides if the project 
continues or not. The practical examples showed in the following sections (definition of 
markets, definition of timelines and economical viability) are a result of 3 fundamental 
Evaluation Meetings (project presentation, project discussion and final conclusion) which 
culminates in a final document/form of the analysis and classification of project idea. 
This concept of integrated development approach contributes to a better communication 
and commitment of all the departments evolved in the success of the project.  
 
Figure 1 – Relation between Evaluation Meetings, their intervenients  and Top management 
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In cross-functional teams (CFT) different specialists of different organizational units find 
together to commonly work on a development project. They share information and take 
decisions about product, process, and production together (Koufteros, 2005). This 
functional and organizational diversity speeds up product development and improves 
development performance (Koufteros, 2005). Mainly, it is ensured that production is 
involved in the development and developed manufacturing processes are viable. A common 
process understanding and unified visions are central to prevent different interpretations 
and to compensate differences (Gerwin, 2002) 
Goals and visions define boundaries for the team to prevent it from constantly re-defining 
itself and its tasks. Team autonomy enables the team to take decisions on its own. 
A general climate supporting cross-functional collaboration is needed. Furthermore, a 
climate of importance and urgency of the project leads to constructive pressure. 
The ideal team mix must be chosen to combine many different skills. By this, different inputs 
can be processed in a most reasonable way. Functional diversity “helps project team 
members to understand the design process more quickly and fully from a variety of 
perspective, and thus it improves design process performance. Moreover, the increased 
information helps the team to catch downstream problems such as manufacturing 
difficulties or market mismatches before they happen, when these problems are generally 
smaller and easier to fix” (Brown, 1995). 
Strong team leadership enables the team. Furthermore, it provides directions for the team 
members without hindering them to work freely. Top management support should be visible 
by commitment to the project and the team. Top management should mainly be helping in 
the case of problems, it should encourage the team and be “making things happen” 
(McDonough, 2000). 
Commitment of all team members is crucial for project success because it leads to common 
efforts in a common direction. Each team member must be willing to contribute to the overall 
project success. (Ziegler, 2014) 
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2.1! Definition of Markets 
The definition of the Market intended to require the Market Authorization for a specific drug 
product is essential to define the steps and the rules needed for guiding the Pharmaceutical 
Development. Despite of the efforts of having requirements and guidelines standard for 
different markets, some activities are not fully harmonized, leading for that reason to 
constraints during development.   
As example, the following table represents some of the differences between the two major 
markets: European and US Market. 
Table 1 - Differences between European and American Market in Pharmaceutical Development 
 US Market EU Market 
Excipients Analysis According to USP According to Ph. Eur. 
Excipients 
Quantities 
According to Inactive 
Ingredient Database No requirements 
Drug Substance 
Analysis According to USP According to Ph. Eur. 
Shape and colour 
of tablets 
Similar to Reference 
Product No requirements 
Release and shelf-
life specifications 
(assay and 
degradation 
products) 
Same specification limits Different specification limits 
Release Dissolution 
Medium 
According to OGD 
requirements 
Dissolution Medium 
developed 
Container Closure 
System 
Presentations to be 
intended for 
commercialization 
(usually bottles) 
Presentations to be 
intended for 
commercialization 
(usually blisters) 
Packaging At a minimum of 100.000 units 
No special quantities 
required 
Process Validation Not required at the time of submission Required 
Design of Clinical 
Trial 
According to OGD 
recommendations 
(usually fast and fed 
conditions) 
No such requirements 
Retention Samples 
for Clinical Trial 
5 times the sample 
required for analysis No such requirements 
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2.2! Definition of Timelines/Milestones 
In the pharmaceutical industry, new substances are filed for patent protection very early in 
the R&D process, often during discovery and before the beginning of product development. 
Thus, longer development time results in a shorter patent protection period during which it 
can be sold exclusively before competitors or generics manufacturer can imitate it. Usually, 
sales decrease up to 80% after patent expiry, mainly due to substitution by cheaper 
generics (Basu, 2010) . As a result, today’s new pharmaceutical products must generate 
more money in less available time. Additionally, there is increasing pressure on drug prices 
by governments. This calls for stable and efficient manufacturing processes right from 
commercial launch to avoid inefficient and thus excessive manufacturing costs.  
 
Figure 2 - Time of patent protection after product launch (CMR International, 2008) 
 
During Evaluation meetings, the patent analysis is one of the topics addressed: is very 
important understand what type of patens are in force and what kind of protection their offer, 
e.g. use of the API, use of specific excipients or use of specific manufacturing process. 
According to this analysis is possible predict the difficulty level of the development. The 
expiry dates of the patents are also very important to estimate the time available to achieve 
the market.  
 A practical example of a patent analysis in the scope of Evaluation meetings is presented 
below. Note that the timelines defined does not correspond to reality, they were used only 
for showing the type of analysis made. 
 
 
 
11 
 
IP Landscape (Patent Analysis) 
“There are no unexpired patents for this product in the Orange Book Data”. Exclusivity data: 
Nov 20, 2017. 
As referred above the patent constraints have impact on the timelines of the project, but it 
is not the single factor. The supply of drug substance, excipients or packaging materials 
can also have an impact in the definition of timelines. A spot in industrial production or even 
the documentation preparation, such as BMRs (Batch Manufacturing Records), PVs 
(Validation Protocols) or later in the process, the submission of IMPDs (Investigational 
Medicinal Product Dossiers) or CTDs (Common Technical Document) are of great 
importance on the project management. 
The clinical trial timelines are also a very important milestone in the scope of the project, as 
it can be seen below with the practical example: 
  
 
12 
Milestones of Clinical Trial  
Table 2 - Milestones of clinical trial 
Milestones Pilot Study (Study 1) Pivotal Study (Study 2 
and 3)* 
IMPD ready T0 T0 
Ethics and  Week 1 Week 1 
Study Approval Week 5 Week 5 
Site Ready Week 6 Week 6 
Screening  Week 6 Week 6 
Period 1 Week 7 Week 7 
Period 2 Week 8 Week 8 
Samples Shipment Week 8 Week 9 
Bioanalytical Results Week 11 Week 13 
Clinical Study Report, Draft Week 13 Week 15 
Clinical Study Report, Final 5 days after Sponsor´s input 5 days after Sponsor´s input 
*Considering that both 
studies will be conducted in 
parallel 
~3.5 months ~4 months 
 
General Milestones of the project 
Table 3 - General Timelines for the project 
Activity/Task Responsibility Estimated Timelines 
Formulation Dev. – Part I Galenical and Analytical Development Dec-16 
Pilot BE 
Galenical and Analytical 
Development/ Medical 
Affairs 
Apr-17 
Formulation Dev. – Part II Galenical and Analytical Development May-17 
Validation 
Galenical and Analytical 
Development/ Production 
Management 
Aug-17 
ICH T=6M Galenical and Analytical Development Mar-18 
BDBE 
Galenical and Analytical 
Development/ Medical 
Affairs 
Jan-18 
Submission Regulatory Affairs Apr-18 
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2.3.! Economical Viability of the Project 
 
Despite of this topic are related to business development is important to refer that the study 
of the markets, including forecasts of sells, costs of APIs, prevision of costs with 
manufacturing and clinical trials are evaluated to know the economic viability of the project.  
A practical example of an economic analysis of development for a generic product is 
expressed below. Note that the costs defined does not correspond to reality, they were used 
only for showing the type of analysis made. 
 
Market Forecasts 
 
Considering the lowest price currently marketed and the expected market share to achieve 
once this development comes to be a product on the market, it is expected an annual 
forecast of 7.500.000 tablets. 
Sales and Consumption 
  
The current USA market accounts for $82,4 million USD referring to a 12 months period 
ending in September 2016. Market intelligence considers that 80% ($65,92 million USD) of 
this market was overtaken by the generics once they became available in 2013. 
Considering that this development will come to be the 3rd or 4th generic on the market it is 
expected that its sales will account for a range from $16.48 million USD to $21.97 million 
USD, considering the “fair share” approach. 
The prices on the market in SEP 2016 are:  
Table 4 -  Prices of Reference Product and generics in US market 
Product Dosage Pack Price 
Reference Product 0,1 mg 1 Tablet 3,07 USD 60 Tablets 184,30 USD 
Generic Product 1 0,1 mg 1 Tablet 3,02 USD 60 Tablets 181,31 USD 
Generic Product 2 0,1 mg 1 Tablet 2,20 USD 60 Tablets 131,81 USD 
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Although there are registered pack sizes of 30’s, 60’s, 180’s and 500’s, data indicates that 
the only presentation on the market is the 60’s. Following the innovator product strategy, 
the 60’s pack is the focus of this development, however the 180’s pack is not to be 
disregarded. 
Competition 
There are currently 3 players on the market, two generic drugs and the reference product. 
Both generic drugs were approved through an ANDA in 2013 and 2015 respectively. No 
other ANDA submissions are known for this product at present time. 
  
Estimated budget for the project:  
 
 
Table 5 - Estimated budget for the project 
BDBE RLD API Project Total Cost 
50.000€ - Pilot 10.000€ 2.000€ approx.. 300.000€ 200.000€ - Pivotal 
 
 
Financial Projections: 
 
In this topic, the company evaluates different scenarios of financial projections: best, base 
and worst scenario. This analysis states the viability of the project for each case.   
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3.!Galenical Development Stage 
3.1.! Quality Target Product Profile (QTTP) 
As discussed before, the quality target product profile forms the basis of design for the 
development of the product. Considerations for the quality target product profile could 
include:  
!! Intended use in clinical setting, route of administration, dosage form, delivery 
systems;  
!! Dosage strength(s);  
!! Container closure system;  
!! Therapeutic moiety release or delivery and attributes affecting pharmacokinetic 
characteristics (e.g., dissolution, aerodynamic performance) appropriate to the drug 
product dosage form being developed;  
!! Drug product quality criteria (e.g., sterility, purity, stability and drug release) 
appropriate for the intended marketed product.  
A CQA is a physical, chemical, biological, or microbiological property or characteristic that 
should be within an appropriate limit, range, or distribution to ensure the desired product 
quality. CQAs are generally associated with the drug substance, excipients, intermediates 
(in-process materials) and drug product.  
CQAs of solid oral dosage forms are typically those aspects affecting product purity, 
strength, drug release and stability. For drug substances, raw materials and intermediates, 
the CQAs can additionally include those properties (e.g., particle size distribution, bulk 
density) that affect drug product CQAs.  
Potential drug product CQAs derived from the quality target product profile and/or prior 
knowledge are used to guide the product and process development. The list of potential 
CQAs can be modified when the formulation and manufacturing process are selected and 
as product knowledge and process understanding increase. Quality risk management can 
be used to prioritize the list of potential CQAs for subsequent evaluation. Relevant CQAs 
can be identified by an iterative process of quality risk management and experimentation 
that assesses the extent to which their variation can have an impact on the quality of the 
drug product.  
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Risk assessment is a valuable science-based process used in quality risk management that 
can aid in identifying which material attributes and process parameters potentially have an 
effect on product CQAs. Risk assessment is typically performed early in the pharmaceutical 
development process and is repeated as more information becomes available and greater 
knowledge is obtained. (ICH Q8(R2), August 2009) 
The following table show an example of a QTPP done in the initial stage on the 
Pharmaceutical development of a generic drug: 
Table 6 - Target Product Profile 
Attribute Target Product Profile Rationale 
 
 
Dosage Form 
 
 
Enteric Film-coated tablets (bilayer) 
Pharmaceutical equivalence 
requirement: same dosage 
form. For identification, use an 
embossed tablet. Tablet Shape 
and Size to facilitate 
swallowing acc.to Guidance for 
Size, Shape, and Other 
Physical Attributes of Generic 
Tablets and Tablets 
Route of administration Oral Pharmaceutical equivalence requirement: 
same route of 
administration 
 
Dosage Strength 
12.5-mg yellow tablets, engraved with X 12.5 
25-mg pink tablets, engraved with X 25 
37.5-mg blue tablets, engraved with X 37.5. 
Pharmaceutical equivalence 
requirement: same strength 
 
 
 
 
Pharmacokinetics 
DS has a complete absorption after oral dosing; the 
elimination half-life is approximately 15 to 20 hours 
after a single dose of Reference Product X. DS 
extensively metabolized and the metabolites are 
considered to be inactive. 
Nonlinearity in pharmacokinetics is observed with 
increasing doses. DS metabolism is mediated in 
part by CYP2D6, and the metabolites are primarily 
excreted in the urine and to some extent in the 
feces 
Bioequivalence requirement. 
Initial plasma concentration 
through the first two hours that 
provides a clinically significant 
therapeutic effect followed by a 
sustained plasma concentration 
that maintains the therapeutic 
effect 
Bioequivalence requirement – 
RLD defined to be used as 
Reference: Name of reference 
Product 
 
Stability 
At least 24 months of shelf-life 
Stored at or below 25ºC ( 77°F ), in the bottle 
tightly closed. 
Equivalent to or better than RLD 
shelf-life 
 
Container closure system 
HDPE Bottles of 30 and 100 counts – 12.5mg and 
25mg 
HDPE Bottles of 30 counts – 37.5 mg 
Needed to achieve the target 
shelf-life and to ensure tablet 
integrity during shipment. 
Administration/ 
Concurrence with labeling 
The tablet is to be taken as single daily dose and 
can be taken with or without food. Similar food 
effect as RLD 
RLD = Name of reference 
Product ( USA ) 
Alternative methods of 
administration None None are listed in the RLD labeling 
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Table 7 - Definition of CQAs 
Quality Attributes of 
the Drug Product Target Product Profile 
Is this 
a 
CQA
? 
Rationale 
 
 
 
 
 
 
 
 
 
 
 
Appearance 
Film coated, double layer, round and 
biconvex tablet. Color and aspect 
acceptable to the patient. No visual 
surface defects observed. 
No 
Color, shape and appearance are 
not directly linked to safety and 
efficacy. Therefore, they are not 
critical. The target is set to ensure 
patient acceptability. 
Pharmaceutical equivalence 
requirements: same dosage form. 
Odor Have no unpleasant odor No 
Generally, a noticeable odor is 
not directly linked to safety and 
efficacy, but odor can affect 
patient acceptability and lead to 
complaints. For this product, 
neither the drug substance nor 
the excipients have an 
unpleasant odor. No organic 
solvents will be used in the drug 
product manufacturing. 
 
 
Size 
 
Round 7mm diameter/ 
Round 8mm diameter 
Yes 
Tablet size correlates to 
swallowability; therefore, it is 
critical. For comparable ease of 
swallowing as well as patient 
acceptance and compliance with 
treatment regimens, the target for 
tablet size and volume is set 
similar to the RLD. 
Equivalent to RLD, size defined by 
dosage. 
Tablet Identification Tablet with a suitable color combination and embossing Yes 
Identification of the correct 
product being produced 
avoiding cross 
contamination. 
Identification Positive for drug substance No 
Formulation and Manufacturing 
Process are unlikely to impact 
identity. 
Assay 100.0%±10% of label claim (for US) Yes 
Variability in assay will affect 
safety and efficacy; therefore, 
assay is critical. 
Formulation and 
Manufacturing Process may 
affect Uniformity. 
Pharmaceutical equivalence 
requirements: meet the same 
or better compendial quality 
standard of product. 
Content Uniformity 
Conforms to USP <905> Uniformity 
of Dosage Units 100% (AV < 15) Yes 
Variability in content uniformity will 
affect safety and efficacy. Content 
uniformity of tablets is critical. 
 
Tablets 
 
Similar drug release profile as RLD 
using a predictive dissolution method 
– OGD media at the following time 
points: 
2h 
3 h 
4 h 
8 h 
10h 
12h 
14h 
 
  Yes 
The drug release profile is 
important for bioavailability and 
bioequivalence (BE); therefore, it 
is critical. Since in vitro drug 
release is a surrogate for in vivo 
performance, a similar drug 
release profile to the RLD is 
targeted to ensure bioequivalence. 
Formulation and Manufacturing 
Process may affect DS release. 
Ph
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Alcohol- induced-
dose dumping 
Comparable or lower drug release 
compared to the RLD in 5% (v/v), 20% 
(v/v), and 40% (v/v) Alcohol USP in  
HCl 0.1N dissolution medium 
The drug release profile in alcohol 
is critical to patient safety. The 
target is set to ensure that alcohol 
stress conditions do not change 
the bioavailability of the generic 
product and introduce additional 
risks to the patient – concomitant 
consumption of alcoholic 
beverages along with these 
products might be expected to 
have the potential to induce dose 
dumping. 
Dose Dumping risk 
Comparable or lower drug release 
compared to the RLD in HCl  0.1 N, 
Acetate pH 4.5 and Phosphate pH 6.8 
dissolution medium. 
The dissolution profiles in the 
different media at varying pH´s 
corresponding to different GI tract 
conditions on the test product 
should show evidence of No Risk 
of dose dumping. 
Degradation Products 
Reporting threshold: Individual unknown 
degradation product: NMT 0.2% 
Total degradation products: NMT 
1.0% (to be proposed) 
Yes 
The limit of degradation products 
is critical to drug product safety. 
The limit for individual unknown 
degradation products complies 
with ICH Q3B - reporting and 
qualification threshold cannot be 
surpassed. A limit for the total 
degradation products is set based 
on analysis of the RLD near 
expiry. 
Residual Solvents Conforms to USP <467> Meet ICHQ3C(R5). limits No 
The drug substance and 
excipients used in the drug 
product formulation contain only 
residual solvents, and the limit 
can be critical to drug product 
safety. However, no organic 
solvent is used in the drug 
product manufacturing process 
and the drug product complies 
with USP <467> Option 1. 
Pharmaceutical equivalence 
requirement: Must meet the same 
compendial or other applicable 
(quality) standards. Levels of ICH 
Q3C (R5) cannot be surpassed. 
Water Content 
To be defined according to the 
RLD characteristics and knowledge 
of the product 
No 
Limited amounts of water in 
oral solid dosage forms will not 
impact patient safety or 
efficacy. Therefore, it is not 
critical. 
Microbial Limits 
Meets relevant pharmacopoeia 
criteria. 
Meet ICHQ4B(4C). limits 
No 
Non-compliance with microbial 
limits will impact patient safety. 
However, as long as raw 
materials comply with compendial 
microbial requirements, the 
formulation and process variables 
are unlikely to impact this CQA. 
Water activity will be tested on 
the final prototype formulation to 
confirm that the drug product 
does not support microbial 
growth. 
Formulation and manufacturing 
process unlikely to affect. 
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3.2.!  Characterization of drug product 
 
3.2.1.! Drug Substance  
The physicochemical and biological properties of the drug substance that can influence the 
performance of the drug product and its manufacturability, or were specifically designed into 
the drug substance (e.g., solid state properties), should be identified and discussed. 
Examples of physicochemical and biological properties that might need to be examined 
include solubility, water content, particle size, crystal properties, biological activity, and 
permeability. These properties could be inter- related and might need to be considered in 
combination.  
To evaluate the potential effect of drug substance physicochemical properties on the 
performance of the drug product, studies on drug product might be warranted. The 
knowledge gained from the studies investigating the potential effect of drug substance 
properties on drug product performance can be used, as appropriate, to justify elements of 
the drug substance specification.  
The compatibility of the drug substance with excipients should be evaluated. For products 
that contain more than one drug substance, the compatibility of the drug substances with 
each other should also be evaluated.  (ICH Q8(R2), August 2009). The compatibility studies 
will be discussed in 3.2.2. section.  
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The following table show a risk assessment of a drug substance done by a development 
project: 
 
Table 9 - Justification of risk assessment of drug substance 
 
Drug 
Substance 
Attributes 
DP CQAs Justification 
 
 
 
 
 
 
 
 
 
 
Solid 
State 
Form 
Assay 
Drug substance solid state form does not affect tablet assay and content 
uniformity. The risk is low. CU 
 
 
Dissolution 
The form of DS hemihydrate was reported in US patent X, and the DS 
manufacturer DMF states that the DS manufactured by XY conforms to the 
polymorphism reported in patent. 
It present Pseudopolymorthism as under extreme dry conditions the bounded 
water can be removed to give anhydrous form, but on rehydration it rapidly 
transforms the API in the hemihydrate form. 
Nevertheless, different polymorphic forms of the drug substance may have 
different solubility and can impact tablet dissolution Thus, further 
clarification/evaluation of polymorphic form must be addressed. The risk can 
be considered medium. 
 
Degradation 
Products 
Drug substance with different polymorphic forms may have different chemical 
stability and may impact the degradation products of the final dosage form. 
Thus, further clarification/evaluation of polymorphic form must be addressed. 
The risk can be considered medium. 
Tablets 
production 
Solid state form of DS has no impact on the performance of the production of 
tablets. 
The risk is low. 
 
 
PK/PD 
The form of DS hemihydrate was reported in US patent X and the DS 
manufacturer DMF states that the DS hemihydrate manufactured by XY 
conforms to the polymorphism reported in patent. 
However, solid state form can affect dissolution profile and thereafter can affect 
bioavailability. The risk is considered medium. 
Table 8 - Risk Assessment of Drug Substance 
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DS Attributes 
Drug 
Products 
CQAs 
Justification 
Particle Size 
Distribution (PSD) 
Assay 
The PSD can impact the blend pharmacotechnical properties. A small particle 
size may adversely impact blend flowability. In extreme cases, poor flowability 
may cause an assay failure and also a content uniformity failure. 
DS represents from 12% to around 30% of the active layer formulation, thus its 
particle size is critical for the development of the drug product. However, the 
manufacturing process involves a wet granulation step, which promotes the 
change of the pharmacotechnical properties of the original DS and of the final 
blend. 
Further evaluation of PSD on drug product attributes is to be considered. The 
risk is considered medium. 
CU 
 
Dissolution 
According to available information, the DS is soluble in different media, but as 
the Drug Product is of sustained release, the PSD can affect dissolution/DS 
release. The impact of PSD on the dissolution profile should be thoroughly 
evaluated. The risk is considered high. 
Degradation 
Products 
It is not expected that PSD will have a significant impact on product degradation 
levels. The risk is considered low. 
 
Tablets 
production 
Even though the proposed manufacturing process is a wet granulation with the 
use of binding agents for the formation of granules, the PSD of the DS can 
impact the manufacturing process, namely granulation and tableting. The risk 
is considered medium. 
PK/PD 
Again, particle size distribution can affect DP release performance. This is 
particularly important for drugs with controlled release profile. The risk is 
medium. 
Particle Shape 
Assay The particle shape can impact the blend pharmacotechnical properties. Needle 
shaped or other ribbon-shaped particles may influence powder flowability. In 
extreme cases, poor flowability may cause an assay failure. However, the 
manufacturing process involves a wet granulation step, which promotes 
alteration of the pharmacotechnical properties of the original DS and of the final 
blend. Thus the risk is considered Low. 
 
CU 
 
 
Dissolution 
Needle shaped or other ribbon-shaped particles may influence powder 
compressibility and ultimately impact drug product dissolution. However, the 
manufacturing process involves a wet granulation step, which promotes 
alteration of the pharmacotechnical properties of the original DS and of the final 
blend. Thus,  the  risk  is  considered Low. 
Deg.Prod. It is not expected that particles shape will have a significant impact on product degradation levels. The risk is considered as low. 
 
Tablets 
production 
Particle shape may affect powder pharmacotechnical properties, namely 
flowability and compressibility. Needle shaped or other ribbon-shaped particles 
may lead to different powder characteristics, affecting the outcome of the 
finished product manufacturing process.  The risk is considered medium. 
PK/PD Particle shape does not affect directly the PK/PD of final drug product. The risk is low. 
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Hygroscopicity 
Assay 
 
DS is considered not hygroscopic. No impact is expected on the assay, content 
uniformity, dissolution and on the degradation products. Additionally, tablets 
dissolution and PK/PD of the final drug product is unrelated to DS 
hygroscopicity.The risk is low. 
CU 
Dissolution 
Degradation 
Products 
Tablet production 
PK/PD 
 
 
 
 
 
Solubility 
Assay 
 
Solubility does not affect tablet assay, content uniformity and degradation 
products. The risk is low. 
CU 
Degradation 
Products 
 
 
 
Dissolution 
DS solubility can affect dissolution/DS release. 
At 25°C, DS hemihydrate is slightly soluble in water, soluble in methanol and 
alcohol. When the acidity of the solution increase from pH 1 to 6, the capacity 
of solubility of DS hemihydrate increase from practically insoluble to slightly 
soluble. 
At pH 7 to 9, DS hemihydrate is practically insoluble. 
It is important to clarify the values of solubility at different physiological pHs, in 
order to assess the impact in dissolution profiles. This topic must be further 
clarified. The risk is medium. 
Tablets 
production Solubility is unrelated with DS production. The risk is low. 
 
 
PK/PD 
Solubility in different solvents is an intrinsic characteristic for a defined 
molecule. The aqueous solubility is a major indicator for the solubility in the 
intestinal fluids and its potential contribution to bioavailability issues. The same 
Drug Substance Salt as compared with the RLD is used on the X project, 
minimizing the risk of BDBE failure due to differences in DS solubility. The risk 
is medium. 
 
 
 
 
 
 
Moisture Content 
Assay 
Moisture is controlled within tight limits in the drug substances specifications 
(2.2% to 2.8%). DS is considered not hygroscopic. However, manufacturing 
process of drug product involves wet granulation step, with the elimination of 
the water added, and therefore loss on dry of the granulated should be 
controlled during the manufacturing process. The risk is considered as low. 
Content 
Uniformity 
Dissolution 
Degradation 
Products 
DS is considered not hygroscopic. It is important to attend to the storage 
conditions of the DS, and define the DS stability to Moisture. Moreover, the 
moisture content of the final drug product should be controlled. The risk is 
considered as medium. 
 
 
Tablet production 
Moisture is controlled within tight limits in the drug substances specifications 
(2.2% to 2.8%). DS is considered not hygroscopic. However, manufacturing 
process of drug product involves wet granulation step with subsequent 
elimination of the solvent / water. This way the loss on dry of the granulated 
should be controlled. The risk is considered Low. 
PK/PD 
Moisture does not affect directly the PK/PD of final drug product. The risk is 
considered low. 
 
 
 
Residual Solvents 
Assay 
 
Residual solvents are controlled in the drug substance specification and comply 
with USP 37. At ppm level, residual solvents are unlikely to impact assay, CU, 
dissolution and degradation products. 
The risk is considered as low. 
Cont. 
Unif. 
Dissolution 
Deg.  Prod. 
Tablets 
production 
PK/PD 
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Chemical 
Stability / Process 
impurities 
Assay 
According to the DMF, results obtained for the studies performed for DS 
Hemihydrate in solid state it can be stated that no degradation was observed 
under tested conditions of humidity, heat and light exposure. Additionally, no 
significant change in the appearance of the sample was observed for these 
stress conditions. 
Based on the results obtained for the studies performed in solution it can be 
stated that no significant degradation was observed under acid hydrolysis. A 
minor degradation was observed under base hydrolysis, oxidation and heat 
conditions. 
A degradation of about 15% was observed under light exposure conditions 
when the sample is in solution. 
The drug substance supplied is consistently pure with total impurities below 
specified limits. This way, Assay is to be monitored during drug product 
production and stability. The risk is considered as high. 
CU 
Dosage form content uniformity is unrelated to drug substance chemical 
stability. 
The risk is considered as low. 
Dissolution 
Tablet dissolution is  unrelated  to  drug  substance  chemical stability. The  
risk  is considered as low. 
 
Deg. Prod. 
Chemical stability may cause significant impact on drug product degradation. 
Impurity profile and degradation will be monitored within the formulation and 
process development. 
The risk is high. 
Tablets 
production 
Chemical stability is not related with tablets production. 
The risk is low. 
 
PK/PD 
Chemical stability of DS can affect the assay and consequently the 
bioavailability. Additionally, it is not desirable the presence of impurities at a 
level superior of certificate of analysis specifications. This is valid for the drug 
substance and thereafter for the final drug product. The risk is considered 
high. 
Optical rotation 
Assay 
 
 
DS Optical Rotation is not related with Assay, Impurities, dissolution nor 
production process. 
The risk is considered low. 
Content 
Uniformity 
Dissolution 
Degradation 
Products 
Tablets 
production 
PK/PD 
It is known that enantiomers have different pharmacokinetic 
(metabolism/elimination) and different pharmacodynamics (S-enantiomer is a 
more potent than R- enantiomer). 
There are two asymmetrical carbon atoms present in the structure of DS, and 
theoretically, there are four enantiomers possible. Actually, there are only two 
enantiomers, (3R, 4S)-isomer and (3S, 4R)-isomer. 
(3S, 4R) isomer is the wanted product, and the other isomer (3R, 4S)-isomer 
is original from the starting material (3S, 4R) Alcohol compound, which is an 
impurity. 
The impurity (3S, 4R) isomer ((+)-trans isomer) in XY finish product are 
determined by a HPLC method and set up the limit NMT 0.10% as per USP, 
and should be controlled on the DP. 
The risk is High. 
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Flow Properties 
 
Assay 
Flow properties of the drug substance can have a significant impact in the 
production process, as well as on the quality of the drug product. Although the 
amount of DS to be used on the formulation is only from around 12% to around 
30%, the pharmacotechnical properties of the drug product can be impacted by 
the drug substance characteristics used on the process. 
However, the manufacturing process involves a wet granulation step with the 
addition of a binder and formation of granules, which promotes alteration of the 
pharmacotechnical properties of the original DS and of the final blend and thus 
on the final drug product quality. This way the risk is Low. CU 
Dissolution 
Flow properties of the DS do not impact the dissolution or the appearance of 
impurities. 
The risk is Low. 
Degradation 
Products 
Tablets 
production 
Flow properties of the drug substance can have a significant impact in the 
production process, as well as on the quality of the drug product. Even though 
the amount of DS to be used on the formulation is not high, the 
pharmacotechnical properties of the drug product can be impacted by the drug 
substance characteristics used on the process. Flow properties may affect 
significantly powder compressibility, affecting the outcome of the finished 
product. 
However, the manufacturing process involves a wet granulation step with the 
addition of a binder and formation of granules, which promotes alteration of the 
pharmacotechnical properties of the original DS and of the final blend and thus 
on the final drug product quality. 
Nevertheless, this topic should be addressed. The risk is medium. 
PK/PD Flow properties of DS does not affect PK/PD of final drug product. The risk is low 
 
The Critical Drug Substance Attributes to be monitored in this specific project should be: 
!! Solid State Form 
!! Particle shape (optical microscopy) 
!! Particle Size Distribution (PSD) 
!! Solubility 
!! Chemical Stability 
!! Moisture content 
!! Optical Rotation 
!! Flow properties 
 
 
 
 
 
 
25 
3.2.1.1.BCS Classification 
Biopharmaceutics classification system (BCS) is a scientific classification of a drug 
substance based on its aqueous solubility and intestinal permeability that correlates 
in vitro dissolution and in vivo bioavailability of drug products (G.L. Amidon, 1995). When 
combined with in vitro dissolution characteristics of the drug product, BCS takes into 
account two major factors: solubility and intestinal permeability, which govern the rate 
and extent of oral drug absorption from solid dosage forms and ultimately, its 
bioavailability (L.X. Yu, 2002). Due to this reason, BCS is the fundamental tool in the 
drug development especially in the development of oral drug products. (science direct, 
2016) 
 
Figure 3 - BCS Classification (particle sciences)  
The food and drug administration (FDA) criterion for solubility classification of a drug in 
BCS is based on the highest dose strength in an immediate release (IR) oral product 
(L.X. Yu, 2002). A drug is considered highly soluble when the highest strength is soluble 
in 250 ml (this volume is derived from typical bioequivalence study protocols) or less of 
aqueous media over the pH range of 1.0–7.5; otherwise the drug substance is 
considered poorly soluble. On the other hand, the permeability classification is based 
directly on the extent of intestinal absorption of a drug substance in humans or indirectly 
on the measurements of the rate of the mass transfer across the human intestinal 
membrane, or in animals, or in vivo models  (L.X. Yu, 2002). A drug substance is 
considered highly permeable when the extent of intestinal absorption is determined to 
be 90% or higher based on mass-balance or in comparison to an intravenous reference 
dose. 
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The bioavailability of BCS class II drugs is likely to be dissolution rate limited. But due to 
their high permeability, the BCS class II drugs have been on focus for solubility 
enhancement researches in the recent times and several formulation approaches for this 
class of compounds has been developed (S. Onoue, 2012). In case of class III drugs, 
the bioavailability is permeability-rate limited, but dissolution is likely to occur rapidly. 
Thus for class III drugs, formulating IR solid dosage forms with absorption enhancers 
can be a viable formulation option to improve their permeability (Y. Kawabata, 2011). But 
in case of BCS class IV compounds, the bioavailability is limited by both dissolution as 
well as intestinal permeability. Because of low membrane permeability, BCS class IV 
drugs are often poor candidates for drug development since solubility and dissolution 
enhancement alone might not help improve their bioavailability. However, these classes 
of compounds cannot be ignored just because of their permeability issues. Therefore the 
current approaches being used for BCS class II drugs, together with absorption 
enhancers, can be applied to formulate class IV compounds (Y. Kawabata, 2011). 
Another formulation development approach for class IV compounds is the selection of a 
better drug candidate with more appropriate physiochemical properties during the lead 
optimization phase (A. Fahr, 2007). (science direct, 2016) 
 
 
3.2.2.! Excipients  
Pharmaceutical powder technology deals with the examining of materials, formulations, 
additives and processes on achieving the desired properties or performance of the 
particles or composites (R.N. Davé, 2013). Particle properties of active drug substances 
or excipients play an important role in the dosage form fabrication and performance. 
Pharmaceutical powder technology also deals with areas of surface engineering!usually 
explored through the applications of surface chemistry and surface morphology. Overall, 
the properties like particle shape, size, adhesiveness, morphology, roughness, 
wettability, density, surface chemistry, plasticity, hardness, brittleness and 
hygroscopicity are important for successful dosage form design and development. 
Ultimately, these strategies are implemented to produce a drug product that is readily 
soluble in the GI tract because incomplete dissolution in the GI tract can severely restrict 
their oral bioavailability drug compounds (J.B. Dressman, 2007). 
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The excipients chosen, their concentration, and the characteristics that can influence the 
drug product performance (e.g., stability, bioavailability) or manufacturability should be 
discussed relative to the respective function of each excipient. This should include all 
substances used in the manufacture of the drug product, whether they appear in the 
finished product or not. Compatibility of excipients with other excipients, where relevant 
(for example, combination of preservatives in a dual preservative system), should be 
established. The ability of excipients (e.g., antioxidants, penetration enhancers, 
disintegrants, release controlling agents) to provide their intended functionality, and to 
perform throughout the intended drug product shelf life, should also be demonstrated. 
The information on excipient performance can be used, as appropriate, to justify the 
choice and quality attributes of the excipient, and to support the justification of the drug 
product specification.  
Information to support the safety of excipients, when appropriate, should be cross- 
referenced. (ICH Q8(R2), August 2009) 
 
The compatibility study of the excipients with the drug substance is very important to 
define the stability of the formulation and define the preliminary quantitative and 
qualitative composition of the drug product. The following tables represent an example 
of a compatibility study design. 
 
Table 10 - Design of Compatibility test (1) 
Sample 
Presentation 25ºC / 60% RH 40ºC / 75% RH Rationale 
 
Individual 
components  
 
 
Open and Closed Flask 
(only test if necessary) 
 
Open and Closed Flask 
(only test if necessary) 
 
The objective is to analyze 
only if inconclusive results 
are obtained in the 
combined mixtures. 
 
 
Binary mixtures 
 
 
Open and Closed Flask 
 
Open and Closed Flask 
 
The objective is to test the 
compatibility profile of the 
combined mixtures under 
forced degradation and long 
term stability conditions. 
 
 
Time points 
 
 
T=1M and T=3M. 
 
 
T=1M and T=3M. 
Two time points 
are enough to take out 
conclusions. 
. 
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Table 11 - Design of Compatibility test (2) 
Sample ID 
0 
day 
1 Month 3 Months 
25/60 40/75 25/60 40/75 
Type of analysis 
Open 
Flask 
Closed 
Flask 
Open 
Flask 
Closed 
Flask 
Open 
Flask 
Closed 
Flask 
Open 
Flask 
Closed 
Flask 
S 
(DS) 
12.5mg T0 S1 S2 S3 S4 S5 S6 S7 S8 
A 
Excipient A 
 - A1 A2 A3 A4 A5 A6 A7 A8 
B 
Excipient B - B1 B2 B3 B4 B5 B6 B7 B8 
C 
Excipient C - C1 C2 C3 C4 C5 C6 C7 C8 
D 
Excipient D - D1 D2 D3 D4 D5 D6 D7 D8 
E 
Excipient E - E1 E2 E3 E4 E5 E6 E7 E8 
F 
Excipient F  F1 F2 F3 F4 F5 F6 F7 F8 
G 
Excipient G + 
Excipient H + 
Excipient I 
 
 
G1 
 
G2 
 
G3 
 
G4 
 
G5 
 
G6 
 
G7 
 
G8 
H 
S + A - 1:1 - H1 H2 H3 H4 H5 H6 H7 H8 
I 
S + B  - 1:1 - I1 I2 I3 I4 I5 I6 I7 I8 
J 
S + C  - 1:1 - J1 J2 J3 J4 J5 J6 J7 J8 
K 
S + D  - 1:1 - K1 K2 K3 K4 K5 K6 K7 K8 
L 
S + E  - 10:1 - L1 L2 L3 L4 L5 L6 L7 L8 
M 
S + F – 10:1 
- M1 M2 M3 M4 M5 M6 M7 M8 
N 
S + G – 1:1 
- N1 N2 N3 N4 N5 N6 N7 N8 
 
The ratio used for compatibility is based on tablets strength, considering a worst case 
scenario where a higher presence of excipient with DS occur. 
The samples were placed in climatic chambers at 25ºC/60% RH (long-term conditions) 
and at 40ºC/75%RH (forced degradation conditions) and the analytical results were 
compiled to better understand if any excipient have impact in the degradation of drug 
substances. 
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3.3.! Manufacturing Process 
The selection, the control, and any improvement of the manufacturing process (i.e., 
intended for commercial production batches) should be explained. It is important to 
consider the critical formulation attributes, together with the available manufacturing 
process options, to address the selection of the manufacturing process and confirm the 
appropriateness of the components. Appropriateness of the equipment used for the 
intended products should be discussed. Process development studies should provide 
the basis for process improvement, process validation, continuous process verification 
(where applicable), and any process control requirements. Where appropriate, such 
studies should address microbiological as well as physical and chemical attributes. The 
knowledge gained from process development studies can be used, as appropriate, to 
justify the drug product specification.  
The manufacturing process development programme or process improvement 
programme should identify any critical process parameters that should be monitored or 
controlled (e.g., granulation end point) to ensure that the product is of the desired quality.  
Significant differences between the manufacturing processes used to produce batches 
for pivotal clinical trials (safety, efficacy, bioavailability, bioequivalence) or primary 
stability studies and the process should be discussed. The discussion should summarise 
the influence of the differences on the performance, manufacturability and quality of the 
product. The information should be presented in a way that facilitates comparison of the 
processes and the corresponding batch analyses information. The information should 
include, for example, (1) the identity (e.g., batch number) and use of the batches 
produced (e.g., bioequivalence study batch number), (2) the manufacturing site, (3) the 
batch size, and (4) any significant equipment differences (e.g., different design, operating 
principle, size).  
To provide flexibility for future process improvement, when describing the development 
of the manufacturing process, it is useful to describe measurement systems that allow 
monitoring of critical attributes or process end-points. Collection of process monitoring 
data during the development of the manufacturing process can provide useful 
information to enhance process understanding. The process control strategies that 
provide process adjustment capabilities to ensure control of all critical attributes should 
be described.  
An assessment of the ability of the process to reliably produce a product of the intended 
quality (e.g., the performance of the manufacturing process under different operating 
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conditions, at different scales, or with different equipment) can be provided. An 
understanding of process robustness can be useful in risk assessment and risk reduction 
and to support future manufacturing and process improvement, especially in conjunction 
with the use of risk management tools. (ICH Q8(R2), August 2009) 
 
Presently, Bluepharma carry out manufacturing operations of non-sterile products / solid 
dosage forms - capsules and tablets. The site is also authorized by the Portuguese 
Health Authority to produce semi-solids, liquids for internal use, suppositories and 
investigational medicinal products. 
Several manufacturing process technologies can be used at production and laboratorial 
facilities in Bluepharma, such as: 
!! Mixture/Blending; 
!! Wet Granulation; 
!! Dry Granulation; 
!! Tabletting, including microtablets and bilayer technology; 
!! Encapsulation of powder, pellets and microtablets; 
!! Coating; 
!! Hot Melt Extrusion. 
 
During development of a new generic drug product is common to find in the bibliography 
and patent analysis the type of manufacturing process used for the manufacturer´s of 
reference product. Information of qualitative formulation can also help to define the type 
of manufacturing technology which should be used (some excipients are almost 
exclusively used in a particular manufacturing process). Despite of that, the study of 
manufacturing process usually begins with direct compression (an easier and cheaper 
process) and escalates to more complex and challenging processes.  After found a 
process with promising analytical results (such as drug release, assay and related 
substances), the process can be finally optimised following a quality by design approach.  
The following table represents a manufacturing risk assessment done for a development 
of a new generic drug product. After defining the critical process steps, they will be 
studied to minimize the risk for the quality of the final product.  
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Table 12 - Manufacturing Risk Assessment 
Drug 
Product 
CQAs 
Process Steps 
Room 
Conditions 
Dry 
Excipients 
Mixing 
Wet 
Granulation 
Wet 
Sieving Drying 
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Table 13 - Justification of manufacturing risk assessment 
Manufacturing 
Steps Parameters 
Drug Product 
CQAs Risk Justification 
 
Room 
Conditions at 
Wet 
Granulation, 
Drying, sizing 
and blending 
Temperature 
and Humidity 
Assay Low If not controlled, fluctuations in the facility 
temperature and RH could impact Drug 
product CQAs. Nevertheless, routine 
environment temperature and RH set point 
in the GMP manufacturing facility is fixed at 
25ºC ± 5% and 40% - 60% respectively, 
and will be monitored during manufacturing. 
The risk is Low 
Mixture 
Homogeneity Low 
Dissolution Low 
Degradation 
Products Low 
Dry Excipients 
Mixing 
Time of 
Mixing 
Assay Low Simple blending process intended to 
promote initial DS homogenization, prior to 
wet granulation. Further wet granulation 
step will take place, promoting DS 
homogeneity within the granulate. This 
parameter is not critical for Assay, 
Dissolution and Impurities. 
The risk is Low 
Dissolution Low 
Degradation 
Products 
 
Low 
Mixture 
Homogeneity 
 
Medium 
Even though it is a simple mixing step to 
promote initial DS homogenization, prior to 
wet granulation step, this should promote 
some initial DS homogeneity to ensure 
proper final product quality. The risk is 
Medium 
Mixer 
Speed 
Assay Low The mixer speed is fixed in galenical 
laboratory equipment to meet the fixed 
speed of industrial equipment, and this 
speed was used during QbD tests. No 
different speed is expected to be used. 
The risk is Low 
Mixture 
Homogeneity Low 
Dissolution Low 
Degradation 
Products Low 
Wet Granulation 
Geometry of 
impeller 
Assay Low 
The geometry of the paddle of the impeller 
in galenical Lab is the same as used on 
production.This parameter is not critical. 
The risk is Low 
Mixture 
Homogeneity Low 
Degradation 
Products Low 
Dissolution Low 
Volume 
of bowl 
occupati
on 
Assay Low The mixture homogeneity, assay and 
degradation products are not influenced by 
granulation bowl occupation, specially due 
to the high amount of DS on the 
formulation. The risk is low. 
Degradation 
Products Low 
Mixture 
Homogeneity Low 
Dissolution  High 
The amount of mass to be granulated can 
impact the characteristics of the final 
granules, possibly impacting the DS 
release under dissolution. 
The risk is high. 
Amount 
of 
granulatio
n solution 
/ amount 
of water 
added 
Dissolution  High 
The amount of water can impact the 
granules characteristics and thus 
dissolution of the DP. This parameter is 
critical for the process and for that reason 
should be tested. Risk is High 
Assay Low It is not expected that amount of water 
added in granulation can impact the assay 
and mixture Homogeneity, specially due to 
the high amount of DS on the formulation. 
The risk is low. 
Mixture 
Homogeneity Low 
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Degradation 
Products 
 
 
Medium 
In this particularly case, since the API is not 
sensitive to moisture, there is no impact of 
amount of water added in granulation in 
degradation products. Nevertheless, the 
impact of water added on DP stability is to 
be verified. 
The risk is medium. 
Granulation 
solution 
addition time 
Assay Low The mixture homogeneity, assay and 
degradation products are not influenced by 
granulation solution addition time, specially 
due to the high amount of DS on the 
formulation. The risk is low. 
Mixture 
Homogeneity Low 
Degradation 
Products Low 
Dissolution High 
The time of addition of granulation solution 
can impact the characteristics of the 
granules and  thus final mixture, and 
possibly impacting the DS release under 
dissolution. 
The risk is high. 
Mixer 
Speed 
Assay Low  
The mixer speed was fixed in galenical 
laboratory equipment to meet the fixed 
speed of industrial equipment, and this 
speed was used during QbD tests. No 
different speed is expected to be used. 
The risk is Low 
Mixture 
Homogeneity 
 
Low 
Dissolution Low 
Degradation 
Products Low 
Chopper 
Speed 
Assay Low 
The chopper is to be used during 
development tests and set to accommodate 
powder flow inside the bowl and promote 
proper wet granules milling, optimizing 
granulation process and to be used in order 
to eliminate agglomerates formation. 
The risk is Low 
Mixture 
Homogeneity Low 
Dissolution Low 
Degradation 
Products Low 
Total time of 
granulation 
process 
 
Dissolution 
 
High 
Wet kneading time can impact the DP 
performance / characteristics, namely 
dissolution profile and tablets 
pharmacotechnical properties (flow, 
tendency to sticking, hardness and 
friability). This is potentially critical. The 
risk is High 
Assay Low 
The mixture homogeneity, assay and 
degradation products are not influenced by 
total wet kneading time. 
The risk is low. 
Mixture 
Homogeneity Low 
Degradation 
Products Low 
 
 
Wet Sieving 
 
Bowl 
Discharge 
Dissolution, 
Assay, Mixture 
Homogeneity, 
Degradation 
Products 
 
 
Low 
As the manufacturing process is a wet 
granulation with the formation of granules, 
it is not expected that the DS or excipients 
get segregated during manipulation, also 
with no impact on degradation products or 
dissolution.  The risk of this step is Low. 
 
 
Sieve 
Size 
Assay Low This simple sieving step through a large 
sieve is used to break any agglomerate 
present on the wet granules, in order to 
facilitate the drying of the granules. 
The risk of this step is Low. 
Mixture 
Homogeneity Low 
Dissolution Low 
Degradation 
Products Low 
Drying Temperature of Drying 
Assay Low 
Drying Temperature is unlikely to impact 
Assay, Content Uniformity or Dissolution. 
The risk is Low. 
Mixture 
Homogeneity Low 
Dissolution Low 
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Degradation 
Products Medium 
If the product is sensitive to temperature, 
the stability can be affected by drying step. 
Nevertheless, forced degradation tests 
performed on the DS indicated no 
degradation of the DS when submitted to 
heat. In any case, in order to mitigate any 
risk, degradation of the product should be 
investigated at different drying 
temperatures.  The risk is Medium 
 
Final LOD 
Assay Low 
Final LOD do not impact Assay and Mixture 
homogeneity. The risk is Low. Mixture Homogeneity Low 
 
Dissolution 
 
Medium 
Final LOD will impact the water present in 
the final mixture. 
Generally, water content may affect 
degradation and microbial growth of the 
drug product and can be a potential CQA. 
In this case, DS is not sensitive to 
hydrolysis and moisture. However, different 
values of LOD will be tested as also as it’s 
impact on stability of the product. 
The risk is medium 
 
Degradation 
Products 
 
Medium 
Granules 
Sieving 
Sieve 
Size 
Assay Low 
The milling step controls the final granule 
size distribution. A suboptimal distribution 
may affect flow, causing variable tablet 
weight and assay during compression. If 
milling generates excessive fines, both bulk 
density and flowability of the blend may be 
impacted, impacting CU. Nevertheless, the 
process leads to granules with good flow, 
and it is not expected to be impacted. 
The risk is Low 
 
Mixture 
Homogeneity 
Low 
 
Dissolution 
 
High 
If milling generates excessive fines or 
coarse particles, may impact DS 
release/dissolution profile. 
The risk is High. 
Degradation 
Products 
 
Low 
Although the screen may heat up during the 
milling process, the dwell time is brief. 
Milling is unlikely to impact degradation 
products. The risk is low. 
Pre-Blend 
Geometry of 
blender 
Assay Low 
The geometry of the blender on galenical 
Lab is the same used in production. This 
parameter is not critical. The risk is Low 
Mixture 
Homogeneity Low 
Dissolution Low 
Degradation 
Products Low 
Time of 
Mixing 
Assay Low The time of blending for homogenization of 
granules and Silica Colloidal does not affect 
the dissolution and the impurities of the 
formulation. 
Generally, the time of blend can have 
impact on the homogeneity of the mixture 
and consequently in the assay and content 
uniformity of the tablets, but on this case 
this step is only to homogenize the 
granulate, and no risk of heterogeneity is 
present. This step is considered Low Risk. 
Mixture 
Homogeneity 
 
Low 
Dissolution Low 
Degradation 
Products Low 
Speed of 
Mixer 
Assay Low 
Rotation speed is fixed by equipment 
constraint. The rotation speed used in 
Galenical Lab is equivalent to the rotation 
speed used in production. No different 
speed is available. Not critical. The risk is 
Low 
Mixture 
Homogeneity Low 
Dissolution Low 
Degradation 
Products Low 
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Final Blend 
Time of 
Lubrication 
Assay  Low As the manufacturing process is wet granulation, over-lubrication is not 
expected to lead to loss of homogeneity. 
This step is considered Low Risk for assay 
and  content uniformity. 
Mixture 
Homogeneity Low 
 
Dissolution 
 
High 
Over-lubrication due to an excessive 
number of revolutions may impact 
disintegration and dissolution of the tablets 
and ultimately the DP performance. 
Therefore the risk is High. 
Degradation 
Products Low 
It is unlikely that lubrication impact 
degradation products. The risk is low 
Rotation 
Speed 
Assay Low Rotation speed is fixed by equipment 
constraint. The rotation speed used in 
Galenical Lab is equivalent to the rotation 
speed used in production. No different 
speed is available. Not critical. 
The risk is Low 
Mixture 
Homogeneity Low 
Dissolution Low 
Degradation 
Products Low 
Bin 
Discharge 
Dissolution, 
Assay, Mixture 
Homogeneity, 
Degradation 
Products 
 
 
Low 
As the manufacturing process is a wet 
granulation, it is not expected that the DS 
gets segregated during manipulation, also 
with no impact on degradation products or 
dissolution.  The risk of this step is Low. 
 
The Critical Drug Substance Attributes to be monitored in this project regarding the 
manufacturing process should be: 
!! The impact of time of mixing of dry excipients in content uniformity; 
!! The impact of Volume of occupation, amount of granulation solution added, 
addition time of granulation solution, total time of granulation process, final LOD, 
sieve size of granules and time of mixing of final blend in dissolution;  
!! The impact of the Amount of solution added, temperature of drying, final LOD in 
degradation products. 
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To simplify the access of manufacturing process, it is very useful the use of flowcharts 
during development. The following figure represents an example of a manufacturing 
process flowchart (until final mixture) of drug product in development. 
 
Figure 4 – Flowchart example of the manufacturing process 
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3.4.! Formulation Development 
A summary should be provided describing the development of the formulation, including 
identification of those attributes that are critical to the quality of the drug product, taking 
into consideration intended usage and route of administration. Information from formal 
experimental designs can be useful in identifying critical or interacting variables that 
might be important to ensure the quality of the drug product.  
The summary should highlight the evolution of the formulation design from initial concept 
up to the final design. This summary should also take into consideration the choice of 
drug product components (e.g., the properties of the drug substance, excipients, 
container closure system, any relevant dosing device), the manufacturing process, and, 
if appropriate, knowledge gained from the development of similar drug product(s).  
Any excipient ranges included in the batch formula should be justified in this section of 
the application; this justification can often be based on the experience gained during 
development or manufacture.  
A summary of formulations used in clinical safety and efficacy and in any relevant 
bioavailability or bioequivalence studies should be provided. Any changes between the 
proposed commercial formulation and those formulations used in pivotal clinical batches 
and primary stability batches should be clearly described and the rationale for the 
changes provided.  
Information from comparative in vitro studies (e.g., dissolution) or comparative in vivo 
studies (e.g., bioequivalence) that links clinical formulations to the proposed commercial 
formulation should be summarized and a cross- reference to the studies (with study 
numbers) should be provided.  
Any special design features of the drug product (e.g., tablet score line, overfill, anti- 
counterfeiting measure as it affects the drug product) should be identified and a rationale 
provided for their use. (ICH Q8(R2), August 2009) 
 
The qualitative formulation derives from bibliography and patent analysis. Following the 
qualitative formulation, a risk assessment study is performed. There the critical points to 
be studied are identified. With the results obtained a quality by design strategy is created 
and followed to achieve the final quantitative formulation. This methodical analysis 
defines limits for the use of excipients according to the quantities described in the 
bibliography. 
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The following drug product critical quality attributes (CQAs) were identified for the tablets 
formulation. 
Table 14 - Risk assessment of formulation 
 
 
 
 
 
 
 
Excipient 
Drug Product Quality Attributes (CQA) 
 
Raw Material Attributes Assay 
Related 
Substances 
 
Dissolution 
 
UDU 
A 
Level Used Low Low High Low 
Grade Low Low High Low 
Loss On Drying [LOD] Low Low Low Low 
Particle Size Distribution [PSD] Low Low Low Low 
Batch to Batch Variability Low Low Medium Low 
B 
Level used Low Low High Low 
LOD Low Low Low Low 
PSD/Specific surface area Low Low Low Low 
Grade Low Low Low Low 
Batch-to-Batch Variability Low Low Low Low 
C 
Level used Low Low Medium Low 
PSD Low Low Medium Low 
Grade Low Low Medium Low 
Batch-to-Batch Variability Low Low Low Low 
D 
 
Level used Low Low High Medium 
LOD Low Low Low Low 
PSD Low Low Low Low 
Grade Low Low Low Low 
Batch-to-Batch Variability Low Low Low Low 
E 
 
Level used Low Low Low Medium 
PSD/Specific surface area Low Low Low Low 
Batch-to-Batch Variability Low Low Low Low 
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Table 15 - Justification of formulation risk assessment 
Excipient 
Material 
attributes CQA 
Initial 
Risk Justification/Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
 
 
LOD, PSD 
 
Assay, Related 
Substances, 
UDU 
Dissolution 
 
 
Low 
LOD and PSD of Excipient A do not directly influence the CQAs of 
the drug product, as Excipient A is solubilized in water for the 
granulation solution. 
From the drug-excipient compatibility studies, it was noticed that 
Excipient A is compatible with the DS, not impacting Assay and 
Related substances. Therefore this risk is low. 
 
 
 
 
 
 
 
 
 
Level used 
 
Dissolution 
 
High 
Excipient A is selected in the formulation as a binding agent. Due 
to the binding nature of the excipient, level of Excipient A might 
influence the dissolution rate of the final dosage form and therefore 
optimization of level of Excipient A in the formulation is important. 
This risk is high. 
 
 
 
Assay 
 
 
 
Low 
Amount of Excipient A used does not correlate with DS assay on 
the drug product, especially considering the high percentage of DS 
on the formulation. 
DS-Excipient compatibility test performed indicate no interaction 
or incompatibility between the DS and Excipient A, and 
additionally, Excipient A is present on the RLD formulation. 
Nevertheless, DP stability will be closely controlled 
throughout development. Therefore this risk is low. 
 
  Related 
Substances 
 
 
Low 
DS-Excipient compatibility test performed indicate no interaction 
or incompatibility between the DS and Excipient A and additionally, 
Excipient A is present on the RLD formulation. 
Nevertheless, DP stability will be closely controlled 
throughout development. Therefore this risk is low 
 
UDU 
 
Low 
Due to the high percentage of DS on the formulation, the 
homogeneity of active on the final mixture is not impacted by the 
Excipient A amount. 
This risk is Low. 
 
 
 
 
Grade / 
Viscosity 
 
 
 
Dissolution 
 
 
 
High 
Excipient A is generally available as different grades with 
differences in viscosities. Grade of Excipient A might influence the 
dissolution rate of the final dosage form due to differences in 
viscosity. Nevertheless, the suitability of this Excipient A grade is 
to be verified during development work. This risk is high.  
Assay, 
Related 
Substances, 
UDU 
 
Low Excipient A grade is not related with UDU, Assay or Related Substances. 
This risk is low. 
 
Batch-to-
Batch 
variability 
Assay, 
UDU, 
Dissolution, 
Related 
Substances 
 
Medium 
Large variation of PSD between batches within the grade could 
impact the process or characteristics of the Drug Product, but 
Excipient A is totally solubilized on the granulation solution, with 
PSD having no impact on the product or process. The risk is 
medium 
 
B 
 
Grade, LOD 
Assay, 
UDU, 
Dissolution, 
Related 
Substances 
 
Low 
Excipient B is used in the formulation as lubricant to facilitate the 
compression. The CQAs of finished product do not get affected by 
the grade and LOD of the magnesium stearate. The risk is low. 
 
PSD/Specific 
surface area 
Assay, 
UDU, 
Dissolution, 
Related 
Substances 
 
Low 
Excipient B is used in the formulation in a very low amount. 
Standard Pharma grade of Excipient B is to be used. The CQAs of 
finished product do not get affected by the PSD. 
The risk is low. 
 
Level used 
 
Related 
substances, 
Assay 
Low In DS- Excipient B compatibility study, no Impurities were formed as well as no reduction of Assay was observed on the samples. 
Additionally, this excipient is present on the RLD. No impact of 
Excipient B is expected on the Assay nor Impurities. Nevertheless, 
it is important to control the product stability screening for 
possibility of degradation. This risk is Low. 
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Dissolution 
 
High 
As Excipient B is a hydrophobic material generally used as a 
lubricant level might impact the dissolution of dosage form. 
Therefore, it is important to control the level of Excipient B in the 
formulation to achieve desired dissolution profile/DP performance. 
The risk is High 
UDU Low No impact of Excipient B is expected on the UDU, especially as the amount of DS on the formulation is very high. This 
risk is Low. 
Assay, Related 
Substances, 
UDU 
Dissolution 
 
Low 
Large variation of PSD and surface area between batches within 
the grade could impact the product performance and 
characteristics, but known experience with the excipient has 
shown that batch to batch variability is minimal, with no impact on 
Drug product quality or performance. The risk is Low 
Batch-to-
Batch 
variability 
Assay, 
Related 
Substances, 
UDU, 
Dissolution 
Low Large variation of PSD and surface area between batches within the grade could impact the product performance and 
characteristics, but given the low amount   of this components, as 
well as known experience with the excipient has shown that 
batch-to-batch variability is minimal, with no impact on Drug 
product quality or performance. The risk is Low 
 
 
 
 
 
 
 
 
 
 
 
 
    C 
 
Batch-to-
Batch 
vairability 
Assay, 
Related 
Substance
s. 
Dissolution. 
UDU 
 
 
Low 
 
Batch-to-Batch variability form of Excipient C do not directly 
influence the CQAs of the drug product. Available manufacturer 
data indicated homogeneity between batches, and therefore this 
risk is low. 
 
 
 
 
 
Level used 
 
 
Dissolution 
 
 
Medium 
From the drug-excipient compatibility studies, it was noticed that 
Excipient C is compatible with the DS. However, being a soluble 
excipient Excipient C may affect the wetting and therefore the 
rate of dissolution of the Dosage Form. This risk is medium. 
Assay, 
Related 
Substance
s; UDU 
 
 
Low 
 
From the drug-excipient compatibility studies, it was noticed that 
Excipient C is compatible with the DS. Level used do not directly 
influence tire CQAs of the drug product and therefore This risk 
is low. 
 
 
 
 
Grade, PSD 
 
 
Dissolution 
 
 
Medium 
Excipient C is generally available in different grades with 
differences of PSD/Flow properties. As the developed drug 
product is a sustained release, the grade of Excipient C might 
influence the dissolution in the final dosage form due to 
differences in physical attributes, especially PSD and bulk 
densities, of lactose grade. The risk is medium. 
Assay, 
Related 
Substance
s; UDU 
 
Low 
 
Excipient C Grade is not expected to influence the CQAs of 
the drug product and therefore this risk is low. 
 
 
 
 
 
 
 
 
 
 
 
 
D  
 
 
LOD, PSD 
 
Assay, 
Dissolution, UDU, 
Related 
Substances 
 
 
Low 
From the drug-excipient compatibility studies, it was noticed that 
Excipient D is compatible with the DS. LOD, PSD, and solid stale 
form of Excipient D do not directly influence the CQAs of the 
drug product and therefore this risk is low. 
 
 
 
 
Level used 
 
Dissolution 
 
High 
Excipient D is selected in the formulation as a binding agent. Due 
to the binding nature of the excipient, level of Excipient D might 
influence the dissolution rate of the final dosage form and 
therefore optimization of level of Excipient D in the formulation is 
important. This risk is high. 
 
UDU 
 
Medium The granule quality, in terms of PSD, homogeneity of active, and flow-properties, is influence by the level of Excipient D 
used formulation. This risk is medium. 
Assay, 
Related 
Substances 
 
Low The level used does not influence the CQAs of the finished dosage form. 
This risk is low 
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Grade 
 
Dissolution 
 
Medium 
Excipient D is generally available as different grades with 
differences in viscosities. Grade of Excipient D might influence 
the dissolution rate of the final dosage form due to differences in 
viscosity. This risk is medium. 
 Assay, UDU, 
Related 
Substances 
 
Low The grade used does not influence the CQAs of the finished dosage form. 
This risk is low 
Batch-to-
Batch 
Variability 
Assay, 
Dissolution, 
UDU, Related 
Substances 
 
Low 
Given the low amount used, as well as the homogeneity 
between the excipient batches, Batch-to-Batch Variability is 
not expected to influence the CQAs of the finished dosage 
form. This risk is low 
 
 
 
 
E  
 
PSD, Batch to 
Batch 
Variability 
 
Assay, 
Dissolution, UDU, 
Related 
Substances 
 
 
Low 
From the drug-excipient compatibility studies, it was noticed 
that Excipient E is compatible with the DS. Excipient E is used 
in the formulation as a glidant to facilitate the flow of the 
granules. Within the normal range of use, this excipient does 
not influence the CQAs of the finished dosage form. 
This risk is low 
 
 
Level used 
 
UDU 
Medium The flow properties of the granules are influenced by grade and PSD of Excipient E and may influence the UDU. 
This risk is medium 
Assay, 
Dissolution, 
Related 
Substances 
Low The level used does not influence the CQAs of the finished 
dosage form. 
This risk is low 
 
Based on the initial Formulation risk analysis performed, the excipients attributes to 
achieve the desired DP performance are: 
!! Excipient A – Amount used 
!! Excipient A - Grade should also be discussed and possibly investigated 
!! Excipient A - Batch to batch variability 
!! Excipient B - Amount used. 
!! Excipient C - PSD and Amount used 
!! Excipient D - Amount used 
!! Excipient E - Amount used 
The following drug product critical quality attributes (CQAs) were identified for the tablets 
formulation. 
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3.5.! Optimization of Formulation Development Vs. 
Manufacturing Process 
In all cases, the product should be designed to meet patients’ needs and the intended 
product performance. Strategies for product development vary from company to 
company and from product to product. The approach to, and extent of, development can 
also vary and should be outlined in the submission. An applicant might choose either an 
empirical approach or a more systematic approach to product development, or a 
combination of both. A more systematic approach to development (also defined as 
quality by design) can include, for example, incorporation of prior knowledge, results of 
studies using design of experiments, use of quality risk management, and use of 
knowledge management throughout the lifecycle of the product. Such a systematic 
approach can enhance achieving the desired quality of the product and help the 
regulators to better understand a company’s strategy. Product and process 
understanding can be updated with the knowledge gained over the product lifecycle.  
Pharmaceutical development should include a control strategy.An enhanced, quality by 
design approach to product development would include the following elements:  
!! A systematic evaluation, understanding and refining of the formulation and 
manufacturing process, including;  
!! Identifying, through e.g., prior knowledge, experimentation, and risk assessment, 
the material attributes and process parameters that can have an effect on product 
CQAs;  
!! Determining the functional relationships that link material attributes and process 
parameters to product CQAs;  
!! Using the enhanced product and process understanding in combination with 
quality risk management to establish an appropriate control strategy which can, 
for example, include a proposal for a design space(s) and/or real-time release 
testing.  
As result, this more systematic approach could facilitate continual improvement and 
innovation throughout the product lifecycle.  
A comprehensive pharmaceutical development approach will generate process and 
product understanding and identify sources of variability. Sources of variability that can 
impact product quality should be identified, appropriately understood, and subsequently 
controlled. Understanding sources of variability and their impact on downstream 
processes or processing, in-process materials, and drug product quality can provide an 
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opportunity to shift controls upstream and minimise the need for end product testing. 
Product and process understanding, in combination with quality risk management, will 
support the control of the process such that the variability (e.g., of raw materials) can be 
compensated for in an adaptable manner to deliver consistent product quality.  
This process understanding can enable an alternative manufacturing paradigm where 
the variability of input materials could be less tightly constrained. Instead it can be 
possible to design an adaptive process step (a step that is responsive to the input 
materials) with appropriate process control to ensure consistent product quality.  
Enhanced understanding of product performance can justify the use of alternative 
approaches to determine that the material is meeting its quality attributes. The use of 
such alternatives could support real time release testing. For example, disintegration 
could serve as a surrogate for dissolution for fast-disintegrating solid forms with highly 
soluble drug substances. Unit dose uniformity performed in-process (e.g., using weight 
variation coupled with near infrared (NIR) assay) can enable real time release testing 
and provide an increased level of quality assurance compared to the traditional end-
product testing using compendial content uniformity standards. Real time release testing 
can replace end product testing, but does not replace the review and quality control steps 
called for under GMP to release the batch.  
A control strategy can include, but is not limited to, the following:  
!! Control of input material attributes (e.g., drug substance, excipients, primary 
packaging materials) based on an understanding of their impact on processability 
or product quality;  
!! Product specification(s);  
!! Controls for unit operations that have an impact on downstream processing or 
product quality (e.g., the impact of drying on degradation, particle size distribution 
of the granulate on dissolution);  
!! In-process or real-time release testing in lieu of end-product testing (e.g. 
measurement and control of CQAs during processing);  
A monitoring program (e.g., full product testing at regular intervals) for verifying 
multivariate prediction models. A control strategy can include different elements. For 
example, one element of the control strategy could rely on end-product testing, whereas 
another could depend on real-time release testing. The rationale for using these 
alternative approaches should be described in the submission. (ICH Q8(R2), August 
2009) 
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Presently, in development companies the development strategy is the combination of an 
empirical development and a systematic development (quality by design). Initially, a 
general analysis of the project allows to understand the intricacies of the product in hand 
(e.g. flow properties of the API, solubility of the API, manufacturing process intended to 
be used, etc.). Later in the development, a quality by design approach can be used 
leading to an optimization of the process and sometimes to an optimization of the quality 
of the final product. The quality by design approach also allows to understand the limits 
of the process, defining in that way the design space where is possible change variables 
without impact the final quality of the product.  
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3.6.! Scale-up and GMP Production 
The goal of technology transfer activities is to transfer product and process knowledge 
between development and manufacturing, and within or between manufacturing sites to 
achieve product realisation. This knowledge forms the basis for the manufacturing 
process, control strategy, process validation approach and ongoing continual 
improvement. (ICH Q10, 2008) 
The commercial manufacturing process must be identical to the process used during 
development and especially during production of material used in late studies. 
Otherwise, there must be additional studies, resulting in increased development costs 
and time (FDA, U.S, 2004). The transfer of the production process from development to 
commercial production is often sped up in order not to waste time and hit the market as 
soon as possible. The transfer is thus often done in a rudimentary manner, with the main 
aim only being enabling basic commercial production. This often results in inefficient 
commercial processes and thus excessive manufacturing costs. Major adaptations to 
commercial scale equipment and environment are omitted to not further increase time-
to-market. 
The early integration of production during development allows ensuring in an early phase 
that the developed processes can be efficiently implemented in a commercial scale and 
with commercial-scale equipment. Data from practical examples demonstrate that 
stronger collaboration of development and production in companies leads to more 
efficient processes. The more advanced a company becomes in integrated development, 
the earlier processes are adapted and optimized to the commercial scale environment. 
Ideally, the processes transferred into commercial production do not need any further 
optimization and do not cause excessive manufacturing costs. In the pharmaceutical 
industry, development and production are separated and work more or less as silo-
organizations. Through an improved collaboration, manufacturing costs could be 
significantly decreased. Furthermore, the continuous increase of development costs and 
time is halted. 
A structured concept adapted to a company’s current set-up facilitates intensified 
collaboration of both Development and Production and leads to the following process-
related or technical advantages: 
!! Manufacturing processes are not adapted as late as technology transfer; instead, 
future manufacturing characteristics are considered earlier during process 
development and scale-up. 
 
46 
!! Early consideration of commercial manufacturing environment and equipment as 
well as a more scientific approach to process development lead to more efficient 
manufacturing processes. 
!! Efficient manufacturing processes have a direct positive influence on 
manufacturing costs. In addition, less post-launch adaptations arise and process. 
(Ziegler, 2014) 
 
Overall, the goals of manufacturing activities include achieving product realisation, 
establishing and maintaining a state of control and facilitating continual improvement. 
The pharmaceutical quality system should assure that the desired product quality is 
routinely met, suitable process performance is achieved, the set of controls are 
appropriate, improvement opportunities are identified and evaluated, and the body of 
knowledge is continually expanded. (ICH Q10, 2008) 
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4.! IMPD Submission to Clinical Trial 
Article 2(d) of Directive 2001/20/EC defines a IMP as follows: 
‘A pharmaceutical form of an active substance or placebo being tested or used as a 
reference in a clinical trial, including products already with a marketing authorisation but 
used or assembled (formulated or packaged) in a way different from the authorised form, 
or when used for an unauthorised indication, or when used to gain further information 
about the authorised form.’ (European Investigational Medicinal Product Dossiers). 
The IMP dossier (IMPD) gives information related to the quality of any IMP (i.e. including 
reference product and placebo), manufacture and control of the IMP, and data from non-
clinical studies and from its clinical use. 
It should be clearly differentiated between the requirements for a dossier for a clinical 
trial and a marketing authorisation dossier. Whilst the latter ones have to ensure a state-
of-the-art quality of a product for wide use in patients, information to be provided for 
investigational medicinal products (IMPs) should focus on the risk aspects and should 
consider the nature of the product, the state of development/clinical phase, patient 
population, nature and severity of the illness as well as type and duration of the clinical 
trial itself. (Guideline on the requirements to the chemical and pharmaceutical quality 
documentation concerning investigational medicinal products in clinical trials. (2006)). 
Since the preparation of the IMPDs varies depending of the products to be submitted for 
approval, it will not be possible to define the detailed requirements applicable for all 
different product. Therefore, it only be discussed the requirements for submission a 
IMPD for a bioequivalence study (generic product versus non-modified comparator 
product authorized in ICH regions).  This section was based in the guideline referred 
above.  
 
Information on the chemical and pharmaceutical quality of authorised, non-modified 
comparator products in clinical trials  
For comparator products to be used in clinical trials which have already been authorised 
in the EU/EEA, in one of the ICH-regions or one of the Mutual Recognition Agreement 
(MRA)-partner countries, it will be sufficient to provide the name of the MA-holder and 
the MA-number as proof for the existence of a MA.  
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For products sourced from those countries outside the EU/EEA, information on the 
analytical methods needed for at least reduced testing (e.g. identity) should be provided. 
The relevant analyses, tests or checks necessary to confirm quality as required by Article 
13 3(c) of directive 2001/20/EC shall therefore be based on proof of existence of the 
equivalent of a marketing authorisation, combined with confirmation of identity.  
The applicant or sponsor of the clinical trial has to ensure that the IMP is stable at least 
for the anticipated duration of the clinical trial in which it will be used. For authorised 
products, it will be sufficient to state the respective expiry date assigned by the 
manufacturer.  
Information on the chemical and pharmaceutical quality of investigational medicinal 
products containing existing active substances in bio-equivalence studies, e.g. generics 
(chemical substances)  
This information is only applied for the test product.  
5.2.1.S DRUG SUBSTANCE  
Reference to an Active Substance Master File or a Certificate of Suitability of the 
European Directorate for the Quality of Medicines is acceptable.  
5.2.1.S.1 General information: 5.2.1.S.1.1 Nomenclature  
Information concerning the nomenclature of the drug substance (e.g. (proposed) INN-
name, pharmacopoeial name, chemical name, code, other names, if any) should be 
given.  
5.2.1.S.1.2 Structure  
The structural formula should be presented.  
5.2.1.S.1.3 General Properties  
The main physicochemical and other relevant properties of the drug substance should 
be indicated.  
5.2.1.S.2 Manufacture: 5.2.1.S.2.1 Manufacturer(s)  
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The name(s) and address(es) and responsibilities of all manufacturer(s), including 
contractors, and each proposed production site involved in manufacture and testing 
should be provided.  
5.2.1.S.2.2 Description of Manufacturing Process and Process Controls  
For substances which comply with a monograph of the Ph. Eur., the pharmacopoeia of 
an EU Member State, USP or JP, no further details are required.  
In cases where reference to a pharmacopoeial monograph listed above cannot be made, 
a brief summary of the synthesis process, a flow chart of the successive steps including, 
for each step, the starting materials, intermediates, solvents, catalysts and reagents 
used should be provided. The stereo- chemical properties of starting materials should 
be discussed, where applicable.  
5.2.1.S.3 Characterisation: 5.2.1.S.3.2 Impurities  
For substances which comply with a monograph of the Ph. Eur., the pharmacopoeia of 
an EU Member State, USP or JP, no further details are required.  
In cases where reference to a pharmacopoeial monograph listed above cannot be made, 
impurities, possible degradation products and residual solvents deriving from the 
manufacturing process or starting materials relevant to the drug substance used for the 
bio-equivalence study should be stated.  
5.2.1.S.4 Control of the Drug Substance: 5.2.1.S.4.1 Specifications  
For substances which comply with a monograph of the Ph. Eur., the pharmacopoeia of 
an EU Member State, USP or JP, no further details are required, provided its suitability 
to adequately control the quality of the active substance from the specific source has 
been demonstrated. The specification should, however, include acceptance criteria for 
any relevant residual solvents and catalysts.  
In cases where reference to a pharmacopoeial monograph listed above cannot be made, 
specifications, tests used as well as the acceptance criteria should be provided for the 
batch(es) of the drug substance(s) intended for use in the bio-equivalence study.  
5.2.1.S.4.2 Analytical Procedures  
Not Applicable (assuming that DS comply with a monograph of the Ph. Eur., the 
pharmacopoeia of an EU Member State, USP or JP). 
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5.2.1.S.4.3 Validation of Analytical Procedures  
Not Applicable (assuming that DS comply with a monograph of the Ph. Eur., the 
pharmacopoeia of an EU Member State, USP or JP). 
5.2.1.S.4.4 Batch Analyses  
Certificates of analyses or batch analysis data for the batch(es) intended for use in the 
planned bio- equivalence study or, in their absence, for representative batches, should 
be supplied. The batch number, batch size, manufacturing site, manufacturing date, 
control methods, acceptance criteria and test results should be listed.  
5.2.1.S.4.5 Justification of Specifications  
Not Applicable (assuming that DS comply with a monograph of the Ph. Eur., the 
pharmacopoeia of an EU Member State, USP or JP). 
5.2.1.S.5 Reference Standards or Materials:  
Not Applicable (assuming that DS comply with a monograph of the Ph. Eur., the 
pharmacopoeia of an EU Member State, USP or JP). 
5.2.1.S.6 Container Closure System:  
The immediate packaging material used for the drug substance should be stated.  
5.2.1.S.7 Stability:  
The available stability data should be provided in a tabulated form. Alternatively, 
confirmation that the active substance will meet specifications at time of use will be 
acceptable.  
5.2.1.P INVESTIGATIONAL MEDICINAL PRODUCT UNDER TEST  
5.2.1.P.1 Description and Composition:  
The qualitative and quantitative composition of the IMP should be stated.  
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Practical Example: 
Table 16 - Composition of drug product 
 
Composition 
 
% 
 
mg/tablet 
DS 0.08 0.10 
Excipient A 30.00 36.00 
Excipient B 29.08 34.90 
Excipient C 38.00 45.60 
Excipient D 1.67 2.00 
Excipient E 0.17 0.20 
Excipient F 1.00 1.20 
TOTAL 100.0
0 
120.00 
 
5.2.1.P.2 Pharmaceutical Development:  
A brief narrative description of the dosage form should be provided.  
 
Practical Example: 
The current IMPD refers to test product tablets (Code name: X), manufactured at 
Bluepharma – Indústria Farmacêutica, S.A., and is intended to support a Clinical Trial 
Application for a Bioequivalence (BE) study. The BE study favourable outcome is going 
to be used to support a Marketing Authorization Application (MAA) in USA for test 
product extended-release tablets. 
The objective of the pharmaceutical development of test product extended-release 
tablets was to obtain a generic medicinal product of the US/FDA-approved reference 
medicinal product marketed in USA which was firstly approved in USA on September 
2009. 
Although the pharmaceutical development was carried-out under the EU GMP 
framework, it was oriented in accordance with the US/FDA requirements, namely in what 
concerns to the use of USP/NF referential for the drug product, drug substance and 
excipients, as well as, to the use of the recommendations on the drug product dissolution 
method and on the BE studies issued by “US/FDA – Office of Generic Drugs”. As outlined 
in the EU Guideline “CHMP/QWP/185401/2004 - Requirements to the Chemical and 
Pharmaceutical Quality Documentation Concerning Investigational Medicinal Products 
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in Clinical Trials”, for IMPs to be used in clinical trials, reference to either the European 
Pharmacopoeia (Ph. Eur.), the Pharmacopoeia of an EU Member State, the United 
States Pharmacopoeia (USP) or the Japanese Pharmacopoeia (JP) is acceptable. 
The pharmaceutical development purpose for test product project was to establish a 
suitable formulation and manufacturing process for test product extended-release 
tablets, the generic drug product of the reference medicinal product, marketed in USA. 
The development encompassed the study of the physical-chemical characteristics of 
reference medicinal product, as well as the active principal ingredient DS. 
The reference medicinal product is presented in the market as round tablets of 0.1mg 
strength. 
The reference medicinal product´s qualitative formulation, which was used as a basis for 
pharmaceutical development of the generic drug, is depicted in the following table: 
 
Table 17 - Qualitative formulation of drug product 
Composition Functional Category 
DS Drug substance 
Excipient A Filler 
Excipient B Binder 
Excipient C Matrix-forming agent 
Excipient D Surfactant 
Excipient E Glidant 
Excipient F Lubricant 
 
During the pharmaceutical development and manufacturing process screening, several 
parameters were tested and the main conclusions are: 
!! Dry granulation, performed with a Roller Compaction process, was considered 
the most suitable process to achieve adequate pharmacotechnical properties of 
the powder mixture, adequate API homogeneity, similarity to the reference 
medicinal product and complete drug substance release under dissolution test; 
!! The final formulation contains qualitatively the same excipients as the reference 
medicinal product (with grades considered adequate; 
!! The critical quality attributes of the drug substance to be used on the test product 
extended-release tablets product were defined regarding particle size and grade; 
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!! The pressure value of the roller unit, fine granulator screens, roller gap are 
considered as Critical Process Parameters to obtain the most suitable 
manufacturing process; 
!! The defined critical process parameters of compression process was 
compression force/ tablet hardness; 
!! Analytical tests showed that the obtained extended-release tablets are within the 
required specifications for assay, dissolution, uniformity of dosage unit, related 
substances, water content, residual solvents as well as good appearance; 
!! The choice of the primary packaging material was based on the characterization 
of the primary packaging materials of the Reference Product Material: HDPE 
bottles (40cc). 
5.2.1.P.3 Manufacture: 5.2.1.P.3.1 Manufacturer(s)  
The name(s) and address(es) and responsibilities of all manufacturer(s), including 
contractors, and each proposed production site involved in manufacture and testing 
should be provided. In case multiple manufacturers contribute to the manufacture of the 
IMP, their respective responsibilities in the manufacturing chain should be clearly 
indicated.  
5.2.1.P.3.2 Batch Formula  
The batch formula for the batch to be used in the planned bio-equivalence study should 
be presented. Where relevant, an appropriate range of batch sizes may be given.  
5.2.1.P.3.3 Description of Manufacturing Process and Process Controls  
A flow chart of the successive steps, including the components used for each step and 
including any relevant in process controls, should be provided. In addition, a brief 
narrative description of the manufacturing process should be included.  
5.2.1.P.3.4 Control of Critical Steps and Intermediates  
If critical manufacturing steps have been identified; their control as well as possible 
intermediates should be documented.  
Should intermediates be stored, assurance should be provided that duration and 
conditions of storage are appropriately controlled.  
5.2.1.P.3.5 Process Validation and/or Evaluation  
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Data are not required, except for non-standard sterilisation processes not described in 
the Ph. Eur., USP or JP and non-standard manufacturing processes.  
5.2.1.P.4 Control of Excipients: 5.2.1.P.4.1 Specifications  
References to the Ph. Eur., the pharmacopoeia of an EU Member State, USP or JP 
should be indicated. For excipients not described in one of the mentioned 
pharmacopoeias, reference to the relevant food- chemical regulations (e.g. FCC) can be 
made. For excipient mixtures composed of pharmacopoeial substances, e.g. pre-
fabricated dry mix for film-coating, a general specification of the mixture will suffice. For 
excipients not covered by any of the afore-mentioned standards, an in-house monograph 
should be provided.  
5.2.1.P.4.2 Analytical procedures  
Not applicable (assuming reference to a pharmacopoeial monograph listed) 
5.2.1.P.4.3 Validation of Analytical Procedures  
Not applicable.  
5.2.1.P.4.4 Justification of Specifications  
Not applicable.  
5.2.1.P.4.5 Excipients of Animal or Human Origin  
Cf. Appendix 7.2.1.A.2.  
5.2.1.P.4.6 Novel Excipients  
For novel excipients, details are to be given on their manufacturing process, 
characterisation and control in relevance to product safety. Information as indicated in 
section 3.2.S of the CTD should be provided in annex 2.1.A.3 consistent with the 
respective clinical phase (c.f. section 7.2.1.A.3), details are to be included on e.g. their 
manufacturing process, characterisation and stability.  
5.2.1.P.5 Control of the Investigational Medicinal Product: 
 5.2.1.P.5.1 Specifications  
The chosen release and shelf-life specifications should be submitted, including test 
methods and acceptance criteria.  
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5.2.1.P.5.2 Analytical Procedures  
The analytical methods should be described for all tests included in the specification (e.g. 
dissolution test method).  
For complex or innovative pharmaceutical forms, a higher level of detail may be required.  
5.2.1.P.5.3 Validation of Analytical Procedures  
The suitability of the analytical methods used should be demonstrated. A tabulated 
summary of the validation results should be provided (e.g. results or values found for 
specificity, linearity, range, accuracy, precision, quantification and detection limit, as 
appropriate). It is not necessary to provide a full validation report.  
5.2.1.P.5.4 Batch Analyses  
Certificates of analysis or batch analysis data for the batch(es) intended to be used in 
the planned bio- equivalence study or, in their absence, representative batches, should 
be provided.  
The batch number, batch size, manufacturing site, manufacturing date, control methods, 
acceptance criteria and the test results should be listed. 
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Practical Example: 
 
Table 18 - Physicalchemical and analytical results of drug product 
 Test Product 
Batch X 
 
 
 
Appearance 
 
White to off-white round, biconvex tablets with debossing: “V” on 
one side and “20” on the other side. 
Identification  
HPLC-RT Complies 
HPLC-PDA Complies 
Weight (mg) Beginning Middle End 
Min 119.6 119.7 120.0 
Max. 122.4 122.0 122.3 
Average 121.2 120.8 121.0 
Diameter (mm) Beginning Middle End 
Min 6.18 6.35 6.36 
Max. 6.27 6.42 6.45 
Average 6.20 6.39 6.41 
Thickness (mm) Beginning Middle End 
Min 3.71 3.75 3.76 
Max. 3.84 3.82 3.82 
Average 3.79 3.79 3.79 
Hardness (N) Beginning Middle End 
Min 38 39 39 
Max. 48 46 46 
Average 42 42 43 
Water content 4.8% 
Assay (%) 99.5 
UDU Complies (AV=4.7) 
Average weight Complies (120.5mg) 
Related Substances 
Impurity A ND 
Impurity M ND 
Single unknown 
impurity ≤0.1% 
Total Impurities ≤0.1% 
Dissolution  
2h Complies at L1: 36% (33.9 - 38.6%) 
4h Complies at L1: 59% (56.1 – 61.9%) 
8h Complies at L1: 81% (77.2 – 84.0%) 
18h Complies at L1: 96% (93.1 – 100.9%) 
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!! Dissolution Profile in HCl 0.01N + Phosphate Buffer pH 7.0 (HPLC) – OGD 
dissolution method 
 
!! Dissolution Profile in HCl 0.1N (HPLC) 
 
 
 
 
Reference Product 
ReRe 
Test Product 
Reference Product 
Test Product 
ReRe 
Figure 5 - Dissolution Profie in OGD method of reference vs test product 
Figure 6 - Dissolution Profile in HCl 0.1N of reference vs test product 
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!! Dissolution Profile in Acetate Buffer pH 4.5 (HPLC) 
 
 
!! Dissolution Profile in Phosphate Buffer pH 6.8 (HPLC)  
 
After analysis of both Test Product Feasibility batch and RLD, it can be stated that: 
!! Regarding Assay, test product Feasibility batch has a similar result when 
compared with RLD 0.1mg ER (99.5 and 99.2%, respectively). 
!! In what concerns UDU, test product Feasibility batch complies with Specification. 
Test Product 
Test Product 
Reference Product 
Test Product 
Reference Product 
Figure 7 - Dissolution Profile in Acetate buffer pH 4.5 of reference vs test product 
Figure 8 - Dissolution Profie in Phosphate buffer pH 6.8 of reference vs test product 
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!! After analysis of Related Substances profile, it can be concluded that test 
product Feasibility batch has a lower impurities profile when compared with RLD 
0.1mg ER, and the results are in accordance with Specification. 
!! Under HCl 0.01N + Phosphate Buffer pH 7.0 (OGD medium), the dissolution 
profile of Test Product Feasibility batch is very similar to RLD. Similarity factor f2 
value (83.47) confirms the in vitro similarity between the Feasibility batch and 
RLD is thus confirmed. 
!! Dissolution profiles in other media also revealed similar results between test 
product and RLD. 
5.2.1.P.5.5 Characterisation of Impurities  
Additional impurities/degradants observed in the IMP, but not covered by section 
5.2.1.S.3.2, should be stated.  
5.2.1.P.5.6 Justification of Specification(s)  
It will be sufficient to briefly justify the specifications and acceptance criteria for 
degradation products and any other parameters that may be relevant to the performance 
of the drug product. Toxicological justification should be given, where appropriate.  
5.2.1.P.6 Reference Standards or Materials:  
The parameters for characterisation of the reference standard should be submitted, if no 
compendial reference standard is available.  
Section 5.2.1.S.5 - Reference Standards or Materials - may be referred to, where 
applicable.  
5.2.1.P.7 Container Closure System:  
The intended immediate packaging and additionally, where relevant for the quality of the 
drug product, the outer packaging to be used for the IMP in the clinical trial, should be 
stated. Where appropriate, reference should be made to the relevant pharmacopoeial 
monograph. If the product is packed in a non-standard administration device, or if non-
compendial materials are used, a description and specifications should be provided. For 
dosage forms where an interaction is unlikely, e.g. solid oral dosage forms, a justification 
for not providing any information may suffice.  
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Practical Example: 
For marketing authorization application purposes, test product tablets are intended to be 
packaged in HDPE bottles with a silica canister containing 1g of silica gel. For the 
bioavailability/bioequivalence study concerned by the current IMPD, unitary doses, 
primary packaged in the bottles, are going to be individualized, per subject, using HDPE 
bottles as container closure system. 
Available stability data presented in the following section proves that the product is stable 
in the concerned container closure systems. 
 
5.2.1.P.8 Stability:  
For bioequivalence studies, it should be confirmed that an ongoing stability program will 
be carried out with the relevant batch(es) and that, prior to the start of the clinical trial, at 
least studies under accelerated and long-term storage conditions will have been initiated. 
The results from at least one month accelerated studies or the results of the initial phase 
of studies under long-term storage conditions should be summarised in a tabulated form. 
Supporting data from development studies should also be summarised in a tabular 
overview. An evaluation of the available data and justification of the proposed shelf-life 
to be assigned to the IMP in the bio-equivalence study should be provided. Extrapolation 
may be used, provided a commitment is included to perform an ongoing stability study 
in parallel to the bioequivalence study.  
Practical example: 
Test Product tablets are packaged in HDPE bottles with a silica canister containing 1g 
of silica gel. For the bioavailability/bioequivalence study concerned by the current IMPD, 
unitary doses, primary packaged in the bottles, are going to be individualized, per 
subject, using HDPE bottles as container closure system. 
 
During Galenical Development work performed, Test Product tablets formulation and 
manufacturing process were developed. Considering Test Product tablets, a laboratorial 
batch was produced (Trial #11B tablets - Batch: 000000000B) according to the final 
formulation. The purpose of this study was to verify how the quality of Test Product 
tablets varies in time under influence of temperature and humidity and to provide 
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evidence of its shelf-life and recommended storage conditions. Analyses were performed 
according to the defined analytical procedure.  
 
Table 19 - Stability results of drug product 
Drug product: X Batch no.: 000000000B 
Date of Storage: 20/07/2016 Manufacturing date: 
11/07/2016  
Storage condition: 40ºC / 75% RH 
Packing material: HDPE 
bottles with a silica canister 
containing 1g of silica gel 
Drug substance: X Batch no. 000000AB 
 
Paramete
r 
 
Specification 
Testing point (month) / results 
0 1M 
Identification 
HPLC-RT  
Must comply 
Complies Complies 
HPLC-PDA Complies Complies 
Assay 90.0 – 
110.0% 
96.51 103.11 
Related substances (HPLC) 
Impurity A 1.0% ND ND 
Impurity B 1.0% ND ND 
Single unknown impurity NMT 1% 0.05 0.06 
Total impurities NMT 3% 0.13 0.18 
Dissolution 
2h 25-45% 37.55 36.40 
4h 50-70% 61.88 60.73 
8h 70-90% 83.18 81.58 
18h NLT 80% 
(Q) 
97.73 97.32 
Average weight Must 
comply 
120.92 125.42 
 
The stability of the Drug Product was accessed also for dissolution profile on Trial #11B 
analysed at T0 and T1M at accelerated conditions, in release medium. 
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Figure 9 - Dissolution profile of drug product T0 vs T1M 
 
Based on the available data for the laboratorial scale batch, after 1 month storage under 
40ºC/75%RH accelerated conditions, the developed test product tablets complies with 
all tested critical parameters, namely assay, impurities and dissolution profile. All tested 
parameters comply with product specification. 
Taking into consideration the presented stability data, it can be concluded that test 
product tablets is stable for at least 2 months in the above mentioned packaging material, 
stored at 25ºC/60%RH. 
Considering that, based on the development data, the stability data of feasibility batch is 
expected to confirm the stability results of the laboratory scale batch (batch no. 
000000000B). 
To confirm the behaviour of the test medicinal product and its shelf life and respective 
recommended storage conditions, a stability program for a feasibility batch of Test 
Product tablets is packaged in HDPE bottles with a silica canister containing 1g of silica 
gel, encompassing test biobatch no. LP000000. This stability test was initiated under 
ICH long-term and accelerated storage conditions. 
Additionally, the applicant establishes the commitment to administer to each subject 
finished product compliant with approved specifications provided in section 2.1.P.5.1. 
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Stability of the clinical batch 
At this early stage of development, expiration / re-test date of the clinical batch (biobatch) 
will be set on the generated stability data of the stability program at a laboratorial-scale. 
At the time of this submission, 1 month of compliant stability data generated with a 
laboratory scale batch at accelerated condition are available (batch no. 0000000000B). 
Taking into consideration the available stability data, test product (biobatch: LP000000) 
can be labelled with an expiry date of at least 2 months after production. 
Post-approval Stability Protocol and Stability Commitment 
Preliminary stability study was designed to be performed for 6 months in long-term 
conditions (25ºC ± 2ºC/60% RH ± 5 %) and 3 months at accelerated conditions (40ºC ± 
2ºC/75% RH ± 5 % RH). 
The applicant commits to yield stability data at accelerated and long term storage 
conditions for test product tablets (biobatch no. LP000000) in HDPE bottles with a silica 
canister containing 1g of silica gel.  
 
 
IMPs Expedition 
After Clinical trial authorization by the regulatory entity, the manufacturer ships the IMPs 
to the CRO. Since the documentation which should go with the IMPs depends to the 
country where the clinical trial will take place, I will only address the documentation 
needed to ship the IMPs from a Portuguese company to a Portuguese CRO. Therefore, 
the documents which should follow the investigational products are: 
-! Certificate of Analysis of the test product biobatch; 
-! Results of Analysis of the RLD biobatch; 
-! Certificate of Compliance (Qualified Person states that the test product batch had 
been manufactured under GMP conditions); 
-! BSE/TSE declaration (quality management states that the formulation of test 
product batch does not contain any ingredient of animal origin nor come in 
contact with animal products during storage or transportation);   
-! Proforma Invoice (stating that the shipped products don´t have commercial 
value). 
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5.! Conclusion 
During the elaboration of this thesis several key points of pharmaceutical development 
where considered. This combination of methodologies and techniques allow for a global 
control of a complex multi-stage development. A tight control of the entire process allows 
for an expedite optimized development.  
The creation of a multidisciplinary team that evaluates all project from their initial stages, 
allows for an intrinsic knowledge of the questions in hand and their difficulties. With the 
cooperation of multiple departments problems can be addressed more efficiently 
reducing delays and failures in the internal communication. 
This organisation has an approach to development based on an empirical and 
systematic processes. By combining both strategies, a general view of the project can 
be achieved as well as in later stages of the project a more precise and methodical 
quality by design approach allows to optimize processes and improve the quality of the 
final product. By using quality by design it is possible to understand the limits of the 
processes and adjust the variables without affecting the quality of the final product. 
The galenical development has a fundamental role in the compilation of the data 
submitted by regulatory affairs for clinical trials. The close contact between the needs of 
the regulatory affair and the data supplied by galenical development are fundamental for 
a higher approval rate from the regulatory entities.  
Even though the pharmaceutical industry is one of the most competitive environments, 
the creation of unrealistic timelines, generally contributes for the unsatisfaction of the 
intervenients as well as the clients. Maintaining a balance between time spent on a 
problem and assuming the end point of the development has been achieved is crucial 
for obtaining the best results. Tight timelines are a necessary evil that allow for a cost 
efficient development but it is normal that such tight schedules have a direct impact on 
the final quality of the product. The creation of a buffer zone during development would 
allow for a higher certainty during development decreasing the chances of failure in later 
stages of the process. This higher investment on the earlier stages of the development 
have a significant lower costs than a failure at later stages of the process, such as during 
production of pilot batches and clinical trials.  
In the same way that a better planning can have a significant impact in realistic timelines, 
the improvement of internal and external communication impacts also in customer´s 
satisfaction and staff´s motivation. However, the continuous improvement of internal and 
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external communication does not mean that the number nor the time of meetings 
between the intervenients of the projects should increase. In fact, through my point of 
view the large number of meetings can be very often time consuming without productive 
results, leading in that way to a lack of efficiency. Well planned meetings during a short 
period of time with key persons can be effective and can improve the understanding of 
the project status.    
Currently Bluepharma evaluates the dissolution profile of the drug products which allows 
to understand the solubility of the API on physiological pHs. However, other type of 
studies, like permeability studies are essential to understand the behaviour of the drug 
substance in-vivo. With this new technique errors during the clinical trial stages could be 
prevented resulting in a more improved product without the necessity of re-run 
bioequivalence studies. 
As the pharmaceutical industry is constantly innovating techniques, processes and 
materials, the staff training is essential for the success of the teams. The technical 
improvement of each collaborator on a specific subject allows have a very specialized 
team in a wide range of subjects instead of a team with a wide range of basic knowledge, 
contributing for the professional improvement of the collaborators results in more 
accomplished, efficient and valued team. 
In summary, the points that I consider that could culminate in an improvement for the 
existing system are: define realistic timelines, have better and more efficient planning 
and improve the internal and external communication. The need of study other type of 
in-vitro tests which can help to predict the results of bioequivalence studies and give to 
the staff more and better training are other critical points that in my opinion should be 
optimised.  
In conclusion, a deeper analysis could be performed for the process of pharmaceutical 
development by conducting an optimization study of existing strategies and possible 
improvements.  
 
 
 
 
 
66 
References 
!! A. Fahr, X. L. (2007). Drug delivery strategies for poorly water-soluble drugs. 
Expert Opin Drug Deliv , pp. pp. 403–416 . 
!! Basu, P. (2010). Improving Pharmaceutical Product Development and 
Manufacturing: Impact on cost of drug development and Cost of Goods Sold for 
pharmaceuticals. Berlin: World Drug Manufacturing Summit. 
!! Bluepharma Site. (n.d.). Retrieved 2016, from 
https://www.bluepharma.pt/about.php 
!! Brown, S. a. (1995). Product development: past research, present findings, and 
future directions. Academy of management review , pp. pp.343–378. 
!! European Investigational Medicinal Product Dossiers. (n.d.). Retrieved from 
http://www.imp-dossier.eu/imdp_guidance/ 
!! FDA, U.S. (2004). Guidance for Industry: Changes to an Approved NDA or 
ANDA. 
!! G.L. Amidon, H. L. (1995). A theoretical basis for a biopharmaceutic drug 
classification: the correlation of in vitro drug product dissolution and in vivo 
bioavailability . pp. pp. 413–420 . 
!! Gerwin, D. a. (2002). n Evaluation of Research on Integrated Product 
Development. Management Science , pp. pp.938–953. 
!! Guideline on the requirements to the chemical and pharmaceutical quality 
documentation concerning investigational medicinal products in clinical trials. 
(2006). committee for medicinal products for human use (CHMP).  
!! H. Leuenberger, M. L. (2005). Pharmaceutical powder technology-from art to 
science: the challenge of the FDA's process analytical technology initiative . Adv 
Powder Technol , pp. pp. 3–25 . 
!! ICH Q10. (2008). PHARMACEUTICAL QUALITY SYSTEM Q10. 
!! ICH Q8(R2). (August 2009). PHARMACEUTICAL DEVELOPMENT Q8(R2). 
!! ICH Q9. (2008). PHARMACEUTICAL QUALITY SYSTEM.  
!! J.B. Dressman, M. V. (2007). Estimating drug solubility in the gastrointestinal 
tract . Adv Drug Deliv Rev , pp. pp. 591–602 . 
 
67 
!! Koufteros, X. V. (2005). nternal and External Integration for Product 
Development: The Contingency Effects of Uncertainty, Equivocality, and Platform 
Strategy. Decision Sciences , pp. pp.97–133. 
!! L.X. Yu, G. A. (2002). Biopharmaceutics classification system: the scientific basis 
for biowaiver extensions . Pharm Res , pp. pp. 921–925 . 
!! McDonough, E. (2000). Investigation of Factors Contributing to the Success of 
Cross-Functional Teams. ournal of Product Innovation Management , pp. 
pp.221–235. 
!! Particle sciences. (n.d.). Retrieved 2016, from 
http://www.particlesciences.com/news/technical-briefs/2011/biopharmaceutical-
classification-system.html 
!! R.N. Davé, E. B. (2013). Special issue on pharmaceutical powders: towards 
developing understanding of the influence of materials and processes on product 
performance . Powder Technol , pp. pp. 1–4 . 
!! S. Onoue, Y. K. (2012). Physicochemical and pharmacokinetic characterization 
of amorphous solid dispersion of tranilast with enhanced solubility in gastric fluid 
and improved oral bioavailability . Drug Metab Pharmacokinet , pp. pp. 379–387  
!! Science direct. (2016). Retrieved from 
http://www.sciencedirect.com/science/article/pii/S1818087614000348 
!! Y. Kawabata, K. W. (2011). Formulation design for poorly water-soluble drugs 
based on biopharmaceutics classification system: basic approaches and 
practical applications. Int J Pharm , pp. pp. 1–10 . 
!! Ziegler, R. M. (2014). Managing Integrated Development in the Pharmaceutical 
Industry: A Cross-Functional Approach to Development of More Efficient 
Manufacturing Processes. Dissertation of the University of St. Gallen, School of 
Management, Economics, Law, Social Sciences and International Affairs. 
 
! ! ! ! ! !
! ! ! !
! ! ! !
 
